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Triple-negative breast cancer (TNBC) is an aggressive subtype that displays extensive intratumor 
heterogeneity and frequently (46%) develops resistance to neoadjuvant chemotherapy (NAC).  Currently, the 
genomic basis of chemoresistance remains poorly understood.  An important question is whether resistance 
to chemotherapy is driven by the selection of rare pre-existing subclones with genomic mutations and 
transcriptional programs that confer resistance to chemotherapy (adaptive resistance) or by the spontaneous 
induction of new mutations and expression changes that confer a resistant phenotype (acquired resistance).  
To investigate this question we applied single cell DNA and RNA sequencing methods and deep-exome 
sequencing to longitudinal time-point samples collected from a cohort of 20 TNBC patients.  Deep-exome 
sequencing of the cohort at three time points revealed patterns of both clonal extinction and clonal 
persistence, with a subset of patients displaying adaptive selection of pre-existing rare mutations.  Single-cell 
copy number profiling of 900 cells from 8 patients also identified an adaptive resistance model, wherein 
minor subclones from the pre-treatment tumors were selected and expanded in response to NAC.  In 
contrast, single cell RNA sequencing of 6,862 cells from 8 patients identified subclones with chemoresistant 
phenotypes that were reprogrammed in response to NAC.  These data suggest that chemoresistance at the 
genotypic level evolves through the selection of pre-existing point mutations and copy number changes, 
while chemoresistance at the phenotypic level evolves through the reprogramming of expression changes in 
signaling pathways associated with chemoresistance.  These characterizations of adaptive and acquired 
resistance shed light on the evolutionary trajectory of chemoresistance in TNBC patients. 
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 1 
CHAPTER 1: INTRODUCTION 
 
1.1 Tr ip l e -Negat iv e  Breas t  Cancer  
Breast cancer is the most common invasive malignancy in women in the United States, with a high 
annual incidence and mortality rate(1, 2).  Clinical categorizations of breast cancer rely primarily on 
estrogen receptor (ER) and progesterone receptor (PR) protein levels, as determined by 
immunohistochemistry (IHC), and human epidermal growth factor receptor 2 (HER2) levels, as 
determined by IHC and/or fluorescence in situ hybridization (FISH)(3).  Triple-negative breast 
cancer (TNBC) – an ER negative, PR negative, and HER2 overexpression negative subtype of breast 
cancer – is particularly aggressive, has a higher rate of visceral metastases(4, 5), and lacks targeted 
therapies, resulting in decreased disease-free survival(2, 6, 7).   
  The standard line of care for TNBC patients includes a combination of paclitaxel, a mitotic 
inhibitor, and anthracycline, a DNA intercalator, but many patients quickly develop resistance and 
are left with no further treatment options.  Although studies indicate that TNBC tumors are more 
sensitive to high-dose chemotherapy than ER positive tumors(8, 9), chemoresistant TNBC patients 
who fail to achieve a pathological complete response (pCR) have significantly worse prognoses than 
non-TNBC breast cancer patients who also fail to achieve pCR(7, 9).  In the neoadjuvant 
Figure 1- Reprinted with permission. © (2018) American Society of Clinical Oncology, From 
Liedtke et al. 2008.  Survival outcomes of TNBC patients.  TNBC patients who achieve pCR (blue 
line) have comparable outcomes to non-TNBC patients who also achieve pCR (yellow line).  
However, TNBC patients who fail to achieve pCR (dotted red line) have significantly worse long-
term outcomes than other breast cancer patients. 
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chemotherapy (NAC) setting, TNBC patients who achieve pCR have long-term survival rates 
comparable to non-TNBC patients with pCR (Figure 1).  However, the clinical trajectory diverges 
with in the absence of pCR: TNBC patients who fail to achieve pCR have significantly worse survival 
outcomes than non-pCR patients of other breast cancer subtypes (Figure 1).    
Studies in pharmacogenomics have categorized gene clusters that may predict resistance to 
paclitaxel or anthracycline(5, 10), but none have traced the genomic and phenotypic evolution of 
tumor cells at the resolution required to identify rare, resistance-associated populations.  Studies in 
cancer genomics have characterized the clonal genotypes of TNBC tumors(11) as well as their 
extensive intratumor heterogeneity(12) and high frequency of TP53 mutations(13), but none have 
investigated longitudinal changes in genotypic and phenotypic subclones.  Moreover, studies in 
residual disease after NAC have identified resistance-associated transcripts and biomarkers(14, 15), 
but none have analyzed the evo lu t ion  of somatic mutations, copy number variations, and 
transcriptomes at the resolution necessary to resolve rare genotypes and phenotypes. 
Some of these gaps in knowledge exist because we have only recently come to understand the 
heterogeneous nature of TNBC in terms of differences between tumor cells within the same tumor 
(intratumor heterogeneity [ITH]).   In 2011, Navin et al. published the first single cell sequencing 
study, which identified diverse copy number aberrations (CNAs) between individual cells from one 
TNBC tumor.  Since then, an increasing number of single-cell studies have focused on CNAs with 
expanded patients cohorts(16), somatic mutations(17, 18), and transcriptional profiles(19) and have 
substantiated TNBC ITH on multiple levels.   
The complex genotypic and phenotypic diversity of TNBC cells introduces the possibility 
that single cell sequencing is necessary to identify resistance-associated subclonal populations, 
because standard bulk sequencing will average the signals from copy number aberration (CNA) 
subclones or transcriptional subclones.  With exome sequencing, it is only possible to establish the 
subclonal structure of tumors if they are sequenced at a sufficiently high depth.  To account for 
TNBC ITH in my investigation of chemoresistance evolution, I conducted deep-exome sequencing, 
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single-cell copy number sequencing, and single-cell RNA sequencing on longitudinal treatment time 
points attained from n=20 TNBC patients. 
My thesis is based on the core principles that guide both species evolution and tumor 
evolution.  In the following chapters, I will explain the evolutionary rationale for my study, followed 
by a description of the technical innovations and experimental approaches that have made it possible 
to investigate the evolution of chemoresistance in triple-negative breast cancer.   
 
1.2 Pr inc ip l e s  o f  [Tumor]  Evo lu t ion 
 
1.2.1 Darwinian Evolution 
 
Darwinian evolution provides the intuitive foundations of bottlenecks and selection, which are 
essential in studying both single tumor cells and tumor populations.   
In 1859, Charles Darwin proposed  
“Let it be borne in mind how infinitely complex and close-fitting are the 
mutual relations of all organic beings to each other and to their physical conditions 
of life.  Can it, then, be thought improbable, seeing that variations useful to man 
have undoubtedly occurred, that other variations useful in some way to each being in 
the great and complex battle of life, should sometimes occur in the course of 
thousands of generations?” 
–  Charles Darwin, “On the Origin of the Species by Means of Natural Selection, 
1859” 
  
An avid naturalist, Darwin was acutely aware of the variations that occurred in species by means of 
both conscious and unconscious selection.  He noted the random variation in breeds of domestic 
pigeon – from the “wide gape of mouth” on the English carrier to the “beak in outline almost like 
that of a finch” on the short-faced tumbler – as well as the variation in a myriad of other plant and 
animal species he encountered during his voyages.  Darwin extrapolated from these observations that 
certain variations allowed individuals to be better suited for specific conditions, thereby imparting 
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“some advantage over a different set of competitors or enemies” in the “struggle for life”.  Without 
any knowledge of genes and genetic heredity, he postulated that a favorable variation, governed by 
random mutation, would “maintain itself in a body and afterward spread, so that the individuals of a 
new variety would chiefly cross together” to create offspring who also carried those traits.  
Environmental factors, including availability of resources, would exert the non-random pressures that 
select for the persistence and propagation of variations that are conducive to survival.  
 Although cancer cells do not reproduce sexually, they have genomic and phenotypic 
variations that confer fitness advantages and undergo natural selection.  In the context of drug 
resistance, therapies produce an exogenous selective pressure that eliminates susceptible cells but 
leaves behind resistant cells to repopulate the tumor after treatment(20).  In an alternative 
evolutionary route, therapies, via genotoxic damage or other mechanisms, can also elicit the 
variations that enable drug resistance(20).  Regardless of the mode by which variations arise, 
Darwinian dynamics govern the selection of variations that confer a fitness advantage to individuals 
and to cancer cells.  We do not consider a tumor cell to be a physiological tabula rasa but rather a 
genetically unique entity with various predispositions that guide survival, drug resistance, metastasis, 
etc.    
 
1.2.2 Modern Applications to Cancer Evolution 
Peter Nowell’s seminal paper published in 1976 posited that cancer progresses in a sequential 
fashion, propagated by the stepwise Darwinian selection of subclones(21).  This process involves 
potential trajectories that become more or less plausible depending on the data set, the context of 
tumor sequencing, and the types of genomic analyses conducted(22).  Place Darwin’s tree of life next 
to any contemporary tumor phylogenetic tree, and you will notice the similarities in the selection of 
subclones that have favorable genomic characteristics.  For instance, the linear evolution model 
suggests that new clones with driver mutations outcompete previous clonal populations, 
overpowering the tumor mass, as evidenced by colorectal cancer progression, where an ordered 
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accumulation of genetic alterations depicts the transition from normal epithelium to adenoma to 
carcinoma(23).  Deep whole genome sequencing (WGS) also indicates linear evolution in acute 
myeloid leukemia (AML) patients who relapse after chemotherapy(24), and loss of heterozygosity 
analyses reveal linear evolution in high-grade serous epithelial ovarian cancer patients with 
metastases(25), indicating that linear evolution can emerge in different clinical settings.  Although 
linear evolution largely decreases ITH, the amount of heterogeneity detected depends on the time 
point of investigation, because a tumor may be sampled at a stage where the dominant clone has not 
Figure 2 - From Davis et al. 2017.    Modes of tumor evolution.  Representations of linear and 
branching evolution (a), where linear evolution displays stepwise replacement of preceding clones 
and branched evolution displays co-existence of diverging subclones (b).  Shown also: neutral 
evolution (c) and punctuated evolution (d) : Davis A., Gao R., Navin N (2017). Tumor evolution: 
Linear, branching, neutral or punctuated? Biochimica et Biophysica Acta (BBA) – Reviews on 
Cancer.  License number: 4316580586200. 
a 
 
 
 
 
 
 
b 
 
 
 
 
 
c 
 
 
 
 
 
 
d 
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yet outcompeted its predecessors(26).  However, many studies in linear evolution have used single 
genes as opposed to genome-wide markers, limiting the accuracy of the model in solid tumors(22). 
 Conversely, the branching evolution model provides a scenario where clones evolve in 
parallel, resulting in a multiclonal tumor and giving rise to ITH via mutations, copy number 
aberrations, and epigenetic changes.  Numerous examples of branching evolution exist in the 
literature, including metastatic renal cell carcinoma(27), primary breast cancer(28), multifocal prostate 
cancer(29), brain metastases(30), hepatocellular carcinoma(31), among others.  Notably, even tumor 
types that display linear evolution in some scenarios can display branching evolution in others (e.g. 
investigating treatment-naïve progression versus pre- and post-treatment samples), alluding to the 
context-specificity of tumor evolution.	 
 In neutral evolution, there are no shifts in clonal fitness over time, and subclones effectively 
grow at similar rates(32), while punctuated evolution is demarcated by early bursts of genomic 
instability followed by periods of relatively stable clonal expansion (Figure 2) (33).  We see some 
aspects of these models in colorectal cancers that expand as multiple intermixed subclones after a 
“big bang” of genomic instability(34).  Neutral evolution, however, contrasts with Darwinian 
principles because it excludes clonal selection as a driver of tumor evolution – but studies on neutral 
evolution are hampered by low-depth data that cannot accurately resolve subclones(32).  In addition, 
there is a possibility that not all identified clones will neutrally progress; clones can compete across 
longitudinal time points, decreasing in number according to relative fitness as time passes.  
 What then is the “most accurate” model of evolution?  Does one even exist?  To date, the 
vast quantity of literature that has been accumulated on tumor evolution strongly supports linear or 
branching trajectories, although there is no way to predict a priori the model that a patient will follow.   
This is further complicated by the fact that there are different genomic evolutionary clocks operating 
within a tumor: for example, copy number evolution has been shown to be punctuated, while 
mutations accumulate throughout tumor evolution(22).  We can presume that certain tumors display 
certain evolutionary trajectories due to variations in the tissues of origin, the selective pressures 
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incurred by the microenvironment, or the clinical treatment regimen, but all these are suppositions 
that must be rigorously tested.  Nonetheless, it is important to note that both linear evolution and 
branching evolution are adaptations of Darwinian theories that signify the wider applicability of 
Darwinian evolution to cancer. 
 
1.2.3 Intratumor Heterogeneity 
We are now aware that tumors are dynamic ecosystems, reflecting an evolutionary course of 
polyclonal expansions, whereby resilient clonal populations are positively selected to expand in 
response to selective pressures(27, 35, 36).  Cancer progression, metastasis, and drug resistance are 
not uniform processes but are characterized by the complex biology of intratumor clonal 
competition.  These considerations are further complicated by the genotypic, phenotypic, and 
epigenetic heterogeneity across different geographical regions and even across single cells within 
individual tumors.  Despite their respective drawbacks, whole-exome sequencing (WES), WGS, 
multi-region sequencing, and single cell sequencing provide snapshots of ITH and show which 
genotypic or phenotypic aberrations are conserved across the majority of spatial regions and single 
cells as early events.  For example, one area of a tumor may have unique subclonal mutations or 
CNAs that are absent in other regions.  Intratumor variations are clinically important, because 
therapies may target subclonal aberrations that exist in only a fraction of the tumor.  Those cells that 
are susceptible to the therapy will be eliminated, while non-susceptible resistant cells will remain 
unaffected and persist as resistant disease.   
 With ITH, different subclones within a tumor display clonal competition for resources(37), 
but clones can coexist in many circumstances.  Merlo and colleagues list the ecological reasons for 
clonal coexistence in their 2006 review paper(37) and emphasize that fitness can decrease due to 
immune predation or clonal parasitism as clones increase in size, allowing competing clones to 
maintain their populations.  Furthermore, clones may experience physical barriers that separate them 
from other clones(38) or adapt to particular niches(39) so that they occupy non-overlapping 
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resources.  Clonal cooperation is also possible, wherein two or more clones are together necessary 
for tumor propagation(40), and a single clone is insufficient to drive tumor growth. 
 Regardless of whether ITH emerges as a stable state (neutral evolution) or as a transient state 
(linear and branched evolution), it encompasses many genomic and phenotypic layers.  The models 
discussed in the previous section focus mainly on data from somatic mutations or CNAs, but ITH in 
cancer is also prevalent at the transcriptomic and epigenetic levels.  Tri-omic sequencing methods 
(scTrio-seq(41)) resolve intratumor subclonal populations based on CNAs, DNA methylation, and 
transcriptomes in hepatocellular carcinoma, and there is a large body of literature that documents the 
roles of single-cell RNA sequencing(19, 42-48) and various modes of epigenetic analyses(49-51) in 
resolving the phenotypic heterogeneity of tumors.  The amount of ITH detected in the genome 
versus the transcriptome or epigenome has not yet been studied in-depth, but the phenotypic 
evolution of transcription and epigenetics can perhaps explain why genomic mutations or CNAs are 
not the only important aspects of tumor growth.  Controversially, a study published in 2015(52) 
posited that tumor initiation could be attributed to “bad luck”, or the accumulation of carcinogenic 
mutations arising randomly during DNA replication(52).  However, this study did not evaluate the 
contributions of transcriptomic and epigenetic clonality in cancer. 
 
1.2.4 Evolutionary Patterns of Resistance 
The identity of resistant subclones is largely dependent on the evolutionary trajectory of the 
tumor, as discussed in detail in Section 1.2.2 and 1.2.3.  However, ITH in itself can provide insight 
on the probability of resistance.  Analyses of chronic lymphocytic leukemia patients show that the 
mere presence of a subclonal driver mutation is an independent risk factor for disease progression 
after treatment(53), suggesting that subclones have the ability to impart fitness advantages.  
Therapeutic agents can be regarded as inducing evolutionary bottlenecks that eliminate susceptible 
tumor cells and select for resistant populations.  It is unclear whether drug resistance arises due to the 
selection and expansion of rare pre-existing subclones (adaptive resistance), or, alternatively, through 
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the induction of new mutations that confer a chemoresistant phenotype (acquired resistance)(54).  
This question has been studied extensively in bacterial systems since the seminal fluctuation 
experiments by Luria & Delbruck(55) in 1952 but remains poorly understood in most human 
cancers. 
There are many limitations to investigating response to therapy in cancer patients: specimen 
availability, specimen quality, and sequencing techniques all restrict the type of studies that can be 
conducted.  Genotypic evolution, via WGS and WES, has been more frequently studied in the 
context of cancer therapy than phenotypic evolution, largely because WGS and WES are well-
characterized, common next-generation sequencing methods in clinical and translational cancer 
research.  Furthermore, WGS and WES are also more widely applicable to clinical samples than bulk 
or single-cell RNAseq, because DNA is not as susceptible to degradation as RNA.  Although existing 
examples of genomic bottlenecks are largely derived from WGS and WES, we can predict that with 
recent advances and modifications in nucleus-based RNAseq, the mechanisms of phenotypic 
evolution will be elucidated for multiple cancer types in the near future. 
Genomic investigations of resistance to targeted therapies often involve compensatory 
activities and alterations in related pathways.  For instance, studies indicate that ER-positive 
metastatic breast cancer patients acquire resistance to endocrine therapy via activating ESR1 
mutations(56), castration-resistant prostate cancer patients acquire resistance to androgen receptor 
antagonists via a F876L mutation in the androgen receptor(57), and colorectal cancer patients acquire 
resistance to EGFR blockade via different KRAS mutations(58).  Alternatively, there are numerous 
examples of adaptive resistance at the genomic level: pre-existing MEK1 mutations confer resistance 
to BRAF inhibitors in metastatic melanoma(59) and pre-existing BRC-ABL kinase domain mutations 
confer resistance to a tyrosine kinase inhibitor in chronic myeloid leukemia(60).  Resistance to 
targeted therapy can also occur at the phenotypic level, involving RNA expression changes in the 
absence of explicit somatic mutations.  BRAF(V600E) mutant melanomas acquire increased EGFR 
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expression(61) and decreased miR-579-3p expression after developing resistance to BRAF 
inhibitors(62). 
Mechanisms of resistance in non-targeted agents like chemotherapies have been more 
difficult to understand, because these drugs can have widespread genotypic and phenotypic effects.  
Even within the sample tumor types, the evolutionary patterns detected by WGS and WES can vary 
from patient to patient.  In AML, WGS before and after chemotherapy (and subsequent relapse) 
reveals different modes of clonal evolution, with some patients gaining relapse-specific mutations 
and others demonstrating a post-treatment expansion of minor clones that existed before 
treatment(24).  In high-grade serous ovarian cancer, platinum-based chemotherapy seems to induce 
somatic mutations in acquired resistance(63), while resistance to cytotoxic chemotherapy in bladder 
urothelial carcinomas is determined by the persistence of pre-existing cell populations(64).   
Previous work on chemoresistance in TNBC patients has focused mainly on in situ 
hybridization methods(65) and bulk genomic profiling methods(14, 15).  Using DNA-FISH and IHC 
for a limited set of markers, the authors of one study showed that genetic diversity did not change in 
response to NAC but mesenchymal phenotypes were selected(65).  Another study used next-
generation sequencing to profile residual disease in post-treatment TNBC chemotherapy samples and 
identified a number of clinically-actionable mutations(15) including TP53, MCL1 and MYC, that 
could be targeted after patients become resistant to chemotherapy.  A third study identified 9p24 
amplifications of JAK2 associated with resistance to chemotherapy in TNBC patients, also providing 
an addition therapeutic target(66).  However these investigations have neither addressed the 
evolutionary question of adaptive versus acquired resistance in TNBC nor have they accounted for 
the considerable genotypic and phenotypic ITH of TNBC tumors. 
 
1.3  Cancer  Genotype  and Cancer  Phenotype  
1.3.1 Beyond DNA 
 11 
The changes that occur in tumors during cancer therapy are multifaceted, involving multiple 
alterations in the genome, transcriptome, epigenome, and proteome(54, 67, 68).  Although studies 
have largely focused on DNA alterations, it is critical not to overlook the various factors that 
contribute to a phenotypic effect.  The distinction between a driver mutation and a passenger 
mutation becomes particularly significant, because not every genotypic aberration influences the 
fitness of a tumor cell.  Likewise, an mRNA transcript may not exert downstream signaling effects, 
because post-transcriptional modifications can prevent its translation.   
There are algorithmic tools that predict and annotate the functional significance of somatic 
mutations from WES or WGS data (e.g. Polyphen(69), SIFT(70, 71)) by using nonsynonymous 
mutations to evaluate the impact of variants on protein structure and function.  Network analyses 
can piece together protein-protein interactions, genetic interactions, and drug-gene interactions to 
understand the functional interactions of genes and proteins(68).  However, these tools are 
probabilistic through computational methods or low-throughput through experimental methods.  
Moreover, predicted amino acid changes do not always indicate proteomic consequences, and we 
have not yet optimized an experimental way to connect the various aspects of genotypic and 
phenotypic evolution in a clinically relevant cancer context. 
The interplay between cancer genotype and phenotype is important to understand, because 
there can be a discordance between the genotypic evolutionary trajectory and the phenotypic 
evolutionary trajectory.  The classification system for breast cancer in itself is an example of such 
dissonance: breast tumors are canonically categorized into subtypes (basal-like, HER2+, normal-
breast-like, luminal epithelial/ER+) according to gene expression(72), but TNBC tumors, which 
largely comprise the basal-like group, share very few common somatic mutations across patients(13).  
In a study conducted in 2014, Almendro and colleagues used ImmunoFISH and found that breast 
cancer patients who achieved a partial response or no response to NAC did not display changes in 
intratumor genotypic diversity but did display observable alterations in phenotypic diversity(65).  This 
integrated analysis of cancer genotype, phenotype, and spatial organization shed light on therapy-
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related tumor evolution in multiple capacities(65).  Nonetheless, the use of ImmunoFISH precluded 
an unbiased analysis of genome-wide changes, and there is still a gap in knowledge regarding the full 
extent of genomic and phenotypic evolution in breast cancer. 
In ideal circumstances, it would be possible to easily assess multiple aspects of tumor 
evolution from the same cell.  As it stands, most genotype-phenotype association experiments either 
use a limited number of biomarkers or conduct sequencing on different sets of cells.  Two methods 
published in 2015, G&T-seq(73) and DR-seq(74), allowed simultaneous genome and transcriptome 
sequencing from a single cell, but these methods remain very low-throughput and expensive, and the 
resulting data have many technical errors due to the physical separation of DNA and RNA prior to 
amplification in each cell. 
 
1.3.2 Gene Dosage Effects  
Similar to somatic mutations, somatic CNAs often exert unclear effects on gene expression.  
Although copy number amplification is broadly correlated with increased gene expression and copy 
number deletion is broadly correlated with decreased gene expression, the associations are not quite 
as straightforward, because there are numerous components that regulate gene expression, such as 
chromosomal hypermethylation.  A study of 77,840 tumor expression profiles observed that 98.9% 
of expressed genes were positively correlated with copy number after accounting for non-genetic 
transcriptional components(75).  In contrast, an investigation of the copy number-altered genome in 
cervical cancer patients showed that only 22.9% of dysregulated genes were copy number-altered(76).  
In breast carcinomas, a subset of genes had a significant correlation between mRNA levels and 
CNAs, but some genes with normal copy number profiles also displayed clinically significant 
expression changes(77).  Perhaps these non-linear relationships can be explained quantitatively: in a 
CNA analysis across 6,691 human genes, a 2-fold change in DNA copy number resulted in a 1.5-fold 
change in mRNA levels(78).  The comparatively smaller change in mRNA may be normalized and 
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thus overlooked depending on the methods of data analysis and the expression of other detected 
genes.	
 On a more global level, aneuploidy of transcriptional regulators in certain regions of the 
genome can influence transcription in genes that reside on other chromosomes(79).  Furthermore, 
aneuploidy can elicit alterations in cell-cycling and create transcriptional changes in pathways related 
to metabolism, inflammation, and cell stress responses(79).  Heterozygotes with null alleles of tumor 
suppressor genes can be haploinsufficient and promote tumorigenesis in particular genetic 
backgrounds(80), revealing the importance of context in gene dosage.   
  
1.3.3 Phenotypic Plasticity and Transcriptional Reprogramming 
Phenotypic plasticity is generally defined as the capacity of a genotype to produce different 
phenotypes(81) and to consequently enable rapid adaptation in a variety of contexts.  In healthy cells, 
plasticity permits beneficial flexibility: plasticity in vascular smooth muscle cells allows repair in 
response to injury(82), plasticity in nephron development converts the metanephric mesenchyme to 
an epithelial phenotype(83), etc.  In cancer cells, phenotypic plasticity yields congruous effects on 
tumor fate, promoting cellular processes that are conducive to progression, metastasis and survival.  
A prime example of this is the phenomenon of epithelial-to-mesenchymal transition (EMT), where 
an epithelial cell acquires changes that portend a mesenchymal cell phenotype(84, 85).  Pleiotropic 
transcriptional repressors such as Snail, Slug, Zeb1, and Twist suppress markers of epithelial 
adhesion(86), propagating cancer metastasis.  This transformation, while standard in normal 
developmental processes, lets carcinoma cells separate from adjacent cells and disseminate to both 
local and distant tissue regions.  Mesenchymal features can also desensitize tumors to cytotoxic 
agents and render them chemoresistant(87, 88).  
  Interactions between tumor cells and the tumor microenvironment contribute to the 
dynamics of phenotypic plasticity, and tumor cells can be reprogrammed in conjunction with changes 
in their neighboring cells, signaling agents, and resources.  For example, M2 macrophages induce 
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EMT when co-cultured with epithelial breast cancer cells(89), and microenvironmental factors like 
glutamine deprivation and TNFα cause melanoma cell de-differentiation(90).  Hypoxia can elicit 
phenotype switching of ROR1-positive melanomas to the ROR2-positive phenotype that is more 
invasive(91).  In hepatocellular carcinomas (HCCs) with constitutive AKT-1 activation, chronic liver 
inflammation caused by 3,5-diethoxycarbonyl-1,4-dihydrocollidine can increase cellular growth and 
proliferation while up-regulating critical genes that contribute to HCC progression(92).  Even 
physical considerations like fluid shear stress versus static culture can elicit EMT in esophageal cancer 
cells(92).   
Indeed, the concept of phenotype plasticity is important in cancer therapy, because it posits 
that cells can reprogram from a less invasive state to a more invasive state and vice versa under cell-
intrinsic or cell-extrinsic conditions.  Phenotypes are more amenable to adaptive modifications than 
genotypes, because they can change accordingly under the cellular or microenvironmental pressures 
of therapy.  While there is much that remains unknown about the precise mechanisms of phenotypic 
plasticity, a growing number of studies are investigating the role of epigenetics in tumor therapy 
resistance, because epigenetic adaptations like DNA hypermethylation of gene promoters are known 
to drive chemoresistance across many cancer types(93).  Case in point, methylation leads to 
transcriptional downregulation of key genes in non-small cell lung cancer, resulting in resistance to 
cisplatin(94).  Likewise, methylation of the hMLH1 promoter in ovarian cancer is associated with 
cisplatin resistance, and exogenous inhibition of methylation re-instates hMLH1 expression and drug 
sensitivity(95).  In alternate scenarios, methylation can be a positive marker for drug sensitivity, as in 
the case of O6-methylguanine-DNA methyltransferase (MGMT) and temozolomide in glioma: 
epigenetic silencing of MGMT is correlated with glioblastoma sensitivity to alkylating agents, leading 
to longer overall survival(96).   
 
1.4  Relevant  Methodo logy  in  Evaluat ing  Tumor Evo lu t ion  v ia  S ing l e  Ce l l  Sequenc ing  
1.4.1 DNA Mutation Profiling Methods 
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Although whole-exome sequencing panels overlook noncoding mutations that may have regulatory 
functions(97, 98), bulk WES is a more affordable means of elucidating ITH, because the exome is 
only ~2% of the genome, and subclonal and clonal mutations can be detected in WES data for clonal 
analyses(99-101).  However, in order to measure clonal substructures, bulk WES data require 
estimations of tumor copy number and tumor purity and do not represent the spatial diversity of 
solid tumors.  One method of accounting for spatial ITH is multi-region sequencing, where different 
sections of a tumor are sampled and sequenced in order to measure genomic diversity.  In ovarian 
cancer, multi-region sequencing demonstrates spatial variation in terms of somatic mutations, copy 
number aberrations, and gene expression, with canonical ovarian cancer drivers altered in only a 
subset of regions(102).  The same is true for other cancer types, including breast cancer(28), renal cell 
cancer(27, 36), lung cancer(103, 104), colorectal cancer(105), and prostate cancer(29).  The limitations 
of multi-region sequencing, however, are related to clinical feasibility, because it is simply impossible 
to acquire multiple biopsies in most clinical scenarios.  While the approach has been enlightening 
from a genomic perspective, it is not practical enough to be broadly applied to a large number of 
patient cases.  Furthermore, multi-region sequencing is even less realistic in studies of therapy 
resistance that require longitudinal samples from ≥2 treatment time points. 
 An alternative way to gauge ITH is single cell sequencing, where single cells from a tumor 
are isolated and profiled for copy number aberrations(12, 16, 106), somatic mutations(17, 18, 107), 
gene expression(42, 108-112), or epigenetic modifications(49, 113-115).  In contrast to multi-region 
sequencing, single cell sequencing can be conducted on individual biopsies, resolving genotypic and 
phenotypic differences across single cells from relatively small tissue samples.  Nevertheless, single 
cell sequencing has its own unique restrictions.  Though the cost-related limitations of single cell 
sequencing have been mitigated to some degree by high-throughput multiplexing techniques, single 
nucleotide variant (SNV) detection in single cells is hampered by the amplification biases of WGA, 
and gene expression analyses in single cells are hindered by sparse gene detection.   There are 
different methods of WGA, including multiple annealing and loop-based amplification 
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(MALBAC)(116), which uses the Bst polymerase, and Phi29-based multiple-displacement-
amplification (MDA)(17), which has fewer false positives than Bst-based MDA.  Regardless, further 
technical improvements are needed to enhance the sensitivity and specificity of single cell sequencing 
for SNVs. 
 Validated panels can be particularly useful in single cell sequencing because they encompass 
a smaller region of the exome and therefore yield a higher coverage depth than WES panels at the 
same number of lanes sequenced.  These panels can be customized to include genes that inform 
clinical decisions, as in The University of Texas MD Anderson Cancer Center’s “T200” panel(117), 
which incorporates 201 genes relevant to cancer from the Catalogue of Somatic Mutations in Cancer 
(COSMIC)(118) and The Cancer Genome Atlas (TCGA).  Targeted multigene panels are currently 
being tested on bulk tissue from numerous clinical settings, such as hereditary cancer risk 
assessment(119), and can feasibly inform ITH when applied to single cells.  
  
1.4.2 DNA Copy Number Profiling Methods 
Many clinical genetics laboratories now evaluate CNAs, copy number variants (CNVs), and copy 
number polymorphisms (CNPs) with single nucleotide polymorphism (SNP) arrays or comparative 
genomic hybridization (CGH) methods(120-122).  Nonetheless, SNP arrays are limited by probe 
distribution and availability, and CGH methods are limited by their inability to accurately determine 
genome-wide loss of heterozygosity (LOH)(123).  As an alternative, low-coverage WGS is an 
unbiased way to sample copy number, delivering high-breadth coverage of the genome and the 
opportunity to discover new breakpoints in samples.  The first single-cell CNA sequencing method 
was developed in 2011 and used WGA on flow-sorted frozen single cells to create next-generation 
sequencing libraries.  Since then, single-cell copy number sequencing has been applied to a variety of 
tumor types and sample types, including formalin-fixed paraffin-embedded samples(106).   
 Multiplex sequencing allows many individually amplified and barcoded sample libraries to be 
sequenced on a single lane and then be sorted during the data analysis process to increase cost-
 17 
efficiency.  For example, SCI-seq uses nucleosome depletion followed by combinatorial indexing to 
sequence thousands of single cells(124), which are demultiplexed during data analysis.   Degenerative-
oligonucleotide-PCR (DOP-PCR)(12, 125) is often used in the WGA step prior to sequencing library 
construction, but recent developments allow direct tagmentation of single-cell DNA without 
preamplification(126). 
 
1.4.3 RNA Sequencing Methods 
New single-cell RNA sequencing methods have distinguished tumor and stromal cell types and have 
led to an improved understanding of cell plasticity and transcription in solid tumors(42, 47, 127).  
Very generally, single-cell RNAseq involves single-cell isolation and mRNA capture followed by 
reverse-transcription and amplification of cDNA(128).  Early iterations of the method include cell 
isolation by micropipeting, laser capture microdissection, or fluorescence-activated cell sorting 
(FACS), although recent advances permit more high-throughput techniques, such as microfluidic and 
microdroplet cell capture(128).   
 There are also differences in the RNAseq chemistry across the methods(129): some systems 
like Smart-seq/C1(130) and Smart-seq2(131) sequence the full-length transcript at the exclusion of 
unique molecular identifiers (UMIs).  In contrast, systems like Drop-seq(112) and MARS-seq(132) 
use UMIs in the absence of full-length sequencing.  Newly released manuscripts(133) (including the 
one featured in Section 3.1) have evaluated the potential of single-nucleus RNAseq as a surrogate for 
single whole-cell RNAseq - the relative advantages of which will be described in Section 3.1. 
 Overall, flexible phenotypes influence clinical trajectories in patients, and (as conducted in 
my thesis) it is therefore meaningful to study genotypes in conjunction with phenotypes when 
tracking tumor evolution during therapy.  Genotypes inform of us of mutational processes and copy 
number aberrations in DNA, while phenotypes inform us of flexible transcriptional alterations that 
dictate cell behavior.  My thesis assesses somatic mutations from bulk tumor populations, single-cell 
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CNAs, and single-cell transcriptomes (albeit all from different cells) to study tumor evolution beyond 
mere DNA alterations. 
 
1.5  Disser ta t ion  Summary  
Triple-negative breast cancer (TNBC) is an aggressive subtype that often develops resistance to 
chemotherapy.  An unresolved question is whether resistance is caused by selection of rare pre-
existing clones, or alternatively through new mutations that are induced by the therapy.  To 
investigate this question, we applied single cell DNA and RNA sequencing, and bulk deep-exome 
sequencing to longitudinal samples from 20 TNBC patients during NAC.  Deep-exome sequencing 
identified 9 patients where NAC led to clonal extinction and 11 patients where clones persisted after 
NAC.  Single-cell DNA sequencing of 900 cells from 8 patients showed that pre-existing copy 
number profiles were adaptively selected by NAC.  In contrast, single-cell RNA sequencing of 6,862 
cells in 8 patients showed that NAC induced new transcriptional programs that conferred a 
chemoresistant phenotype.  Our data suggest a model for chemoresistance in which adaptive 
selection of genotypes is followed by the transcriptional reprograming of chemoresistant phenotypes. 
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CHAPTER 2: MATERIALS AND METHODS 
 
[Note: This chapter is based on published material from Gao and Kim et al. 2017 (Gao, R and Kim, 
C. et al. Nanogrid Single-Nucleus RNA Sequencing Reveals Phenotypic Diversity in Breast Cancer 
Nat Commun 8, doi:doi:10.1038/s41467-017-00244-w, 2017) as well as a manuscript that has been 
accepted by Cell (Kim and Gao et al. 2018).  Nat Commun articles are published under a CC BY 
license (Creative Commons Attribution 4.0 International License), which establishes that authors 
retain copyright in their articles.] 
 
2.1 Mater ia l s  
2.1.1 Human Patient Cohort  
Fresh triple-negative breast cancer (TNBC) tissue samples were obtained from the Predict Response 
of Preoperative Treatment of Breast Cancer Early (PROMIX: NCT00957125) trial in collaboration 
with Dr. Theodoros Foukakis at the Karolinska University Hospital and with material transfer 
agreement (MTA) approval by the Internal Review Board (IRB) at the University of Texas MD 
Anderson Cancer Center and Karolinska University Hospital.  The triple-negative status of all tumor 
samples was determined by standard immunohistochemistry. 
The PROMIX trial recruited patients with localized, primary breast cancer, including 
inflammatory breast cancer, suitable for primary medical treatment and/or patients with regional 
lymph node metastases, including ipsilateral supraclavicular nodes, with breast cancer diagnoses 
confirmed by histological examination with or without tumor lesions in the breast (Figure 3).  
PROMIX’s purpose was to evaluate patient response to six cycles of chemotherapy with epirubicin 
and docetaxel +/- bevacizumab by mammography, ultrasound, several functional imaging techniques 
(MR, CT-PET, contrast-enhanced ultrasound), and biological markers detected from fresh tumor 
samples.  The trial adhered to the ethical principles recommended by the Declaration of Helsinki, 
was approved by institutional review, and followed the quality standards of Good Clinical Practice 
(GCP).   
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Tumor tissue samples were collected <2 weeks prior to treatment initiation (14G core 
biopsy), after 2 cycles of 75 mg/m2 epirubicin and 75 mg/m2 docetaxel (14G core biopsy), and after 
4 additional cycles of 75 mg/m2 epirubicin and 75 mg/m2 docetaxel in combination with 15 mg/kg 
bevacizumab (surgical excision).  Tumor tissue from the 14G biopsies were placed on microscope 
slides for imprinting and then dry-compressed without addition of fluids.  Afterwards, samples were 
placed in tubes and snap-frozen immediately or after a maximum delay of 10 minutes.  We 
retrospectively received the de-identified frozen samples for genomic analyses. 
 
2.1.2 Breast Cancer Tissue Samples and Cell Lines for Nanogrid Single-Nucleus RNA Sequencing Validation 
Breast cancer cell lines were obtained from Characterized Cell Line Core (CCLC) Facility at the 
University of Texas M.D. Anderson Cancer Center, Houston, TX to validate our nanogrid-based 
single-nucleus RNA sequencing technology.  All cell lines were mycoplasma-negative and 
authenticated with the Short Tandem Repeat (STR) method by the CCLC facility.  Fresh tumor 
tissue from an invasive ductal carcinoma patient was obtained in collaboration with Dr. Hong Zhang 
at MD Anderson Cancer Center, under approval by the Internal Review Board (IRB) at the 
University of Texas MD Anderson Cancer Center.  The triple-negative status of this tumor sample 
was determined by IHC for estrogen receptor (<1%) and progesterone receptor (<1%), and FISH 
analysis of HER2 amplification using the CEP-17 centromere control probe (ratio of HER2/CEP-17 
pre-treatment 
core biopsy 
mid-treatment 
core biopsy 
post-treatment 
operative excision 
2 cycles 
Epirubicin + 
Docetaxel 
6 cycles 
Epirubicin + 
Docetaxel + 
Bevacizumab 
SD/PR 
Figure 3 - Timeline of chemotherapy treatment schedule and sample acquisition.  A pre-treatment 
core biopsy was obtained prior to NAC, a mid-treatment core biopsy was attained after two cycles of 
NAC (docetaxel and epirubicin), and the surgical sample was obtained after four additional cycles of 
NAC in combination with bevacizumab. 
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< 2.2).  This tumor sample was also used in the technology development and validation steps for our 
single-nucleus RNA sequencing system. 
 
2.2 Appl i ca t ion  o f  Exis t ing  Bulk Next-Genera t ion Sequenc ing  Methods  
2.2.1 Whole-Exome Sequencing 
Bulk genomic DNA was extracted from frozen tumor samples following the manufacturer’s 
instructions outlined in the DNA Mini Kit (Qiagen, #51306).  Germline genomic DNA was 
extracted from matched patient blood samples with the DNA Blood Mini Kit (Qiagen, #51106).  
Extracted DNA was sonicated to 250 bp using the S220 Sonicater (Covaris).  KAPA Hyper libraries 
(KAPA Biosystems, #8502) were constructed from the sonicated DNA according to manufacturer’s 
instructions using 10-250 ng of input DNA and unique NEXTflex-96 barcodes (Bio Scientific) for 
each individual sample.  Libraries (8-12) were pooled together and underwent exome captures using 
the SeqCap EZ v2 (Roche, #06953212001), which constituted 44 Mb of the genome.  Final v2 
exome capture products were quantified with Qubit dsDNA HS Fluorometric Assay, Agilent’s High 
Sensitivity DNA Chip, and KAPA HIFI and sequenced at 100 paired-end cycles on the HiSeq2000 
or HiSeq4000 system (Illumina) in the Sequencing Core Facility of the Genetics Department at MD 
Anderson Cancer Center.			
2.2.2 Targeted Amplicon Sequencing 
Forward and reverse primers were designed to incorporate ~150 bp regions containing the variant 
sites of interest identified by bulk exome sequencing for the tumor sample and its matched blood 
sample.  Amplicons were PCR-amplified, purified, eluted in ~20µL H2O, and run on an agarose gel 
to confirm fragment sizes.  They were then pooled together in equimolar concentrations and 
sonicated to 250 bp.  A New England BioLabs kit was used for end repair of amplification products 
(NEB, E6050L), and amplicon products were subsequently purified with the DNA Clean and 
Concentrator-5 Kit (Zymo Research, #2404).  The NEBNext DNA Library Prep enzymes were used 
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for 3’ adenylation, adapter ligation, and PCR amplification to barcode the library with a P7 unique 8-
bp identifier.  The final barcoded library was quantified by quantitative PCR using the KAPA Library 
Quantification kit (KAPA Biosystems, KK4835) and the QuantStudio 6 Flex Real-Time PCR System 
(Thermo Fisher Scientific).  The sample was placed on the MiSeq system (Illumina) for sequencing.   
 
2.3 Whole -Exome Sequenc ing  Data Analys i s  
2.3.1 Variant Calling 
FASTQ files were mapped to the human assembly US National Center for Biotechnology 
Information build 37 (hg19) using the Bowtie2(134) alignment software.  Samtools (0.1.19)(135)  was 
used to convert SAM files to compressed BAM files and to sort the BAM files by chromosomal 
coordinates(135).  PCR duplicates were marked with Picard (1.56), and the sorted, marked BAM files 
were realigned with the Genome Analysis Toolkit (GATK 1.4-37)(136) at intervals with indel 
mismatches.  GATK was also used to detect single nucleotide variants (SNVs), and all samples within 
an experiment were processed into one VCF4 file.  Variants that had at least 30x coverage across all 
corresponding longitudinal and matched blood samples were selected and further filtered so that a 
mutation was only considered a true mutation if it met the aforementioned criterion and had at least 
5 variant reads.  Germline variants were removed by filtering out variants in the normal samples, and 
SNVs and indels were annotated downstream with Annovar(137), dbSNP build135(138), 
1000Genomes(139), Polyphen(69), SIFT(70, 71), MutationTaster(140), and COSMIC(118).  
 
2.3.2 Mutation Clustering 
Non-synonymous somatic mutations were identified in the bulk exome sequencing data for 20 
TNBC patients with 2 or 3 longitudinal samples. Bulk tumor genomic copy number profiles were 
estimated from the pair-end exome sequencing depth using the R package ‘exomeCNV’(141). Tumor 
purity was estimated as the maximum variant allele frequency in each tumor. The variant allele 
frequencies from each point mutation were normalized with both exome-derived copy number 
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profiles and estimated tumor purities, and initial clusters were identified using PyClone2 
(v0.12.9)(142). Mutation clusters with only one mutation were excluded from further analysis. The 
PyClone cluster frequencies were calculated as the mean variant allele frequencies of mutations 
within each cluster. The final clonal inferences of somatic mutation were performed using 
CITUP(143) by evaluating the optimal tree and the clustering adjustment across all the tumor time 
points from same patient.    
 
2.3.3 Targeted Amplicon Sequencing Data Analysis 
Forward and reverse primers were designed to amplify ~150 bp regions containing the targeted 
mutation site identified by bulk exome sequencing for the tumor sample and its matched blood 
sample.  Amplicons were PCR-amplified, purified, eluted in ~20µL H2O, and run on an agarose gel 
to confirm fragment sizes.  Fragments were pooled together in equimolar concentrations, and the 
larger amplicons were sonicated.  A New England BioLabs kit was used for end repair of 
amplification products (NEB, E6050L), and amplicon products were subsequently purified with the 
DNA Clean and Concentrator-5 Kit (Zymo Research, #11-303). NEBNext DNA Library Prep 
enzymes were used for 3’ adenylation (#E6053L), adapter ligation (#M0202L), and PCR 
amplification (#M0541L) to barcode the library with a P7 unique NEXTflex-96 barcode.  The final 
barcoded library was quantified by quantitative PCR using the KAPA Library Quantification kit. The 
sample was sequenced on the MiSeq system (Illumina #MS-102-3001, 150 single-read).  
DeepSNV(144) was applied to determine whether mutations were statistically significant and present 
at higher levels in the tumor samples compared to the matched normal blood samples at a p-value < 
0.05, with 5 bp flanking regions around the mutation site of interest to establish error rates. 
 
2 .4 Appl i ca t ion  o f  Exis t ing  S ing l e -Ce l l  Next-Genera t ion Sequenc ing  Methods  
The protocol published by Gao et al. 2016 was used to multiplex single nuclei for copy number 
sequencing.  Briefly, nuclei from frozen tumors were isolated by mincing the tumor in DAPI-NST 
 24 
buffer (800 mL of NST [146 mM NaCl, 10 mM Tris base at pH 7.8, 1 mM CaCl2, 21 mM MgCl2, 
0.05% BSA, 0.2% Nonidet P-40]), 200 mL of 106 mM MgCl2, 10 mg of DAPI, and 5mM EDTA) 
and filtering through a 37-µM nylon-mesh filter(16).  Single nuclei from the aneuploid distribution 
were flow-sorted into 96-well plates through the FACSAria II flow cytometer.  Each individual well 
contained 10 µL of lysis solution from the Sigma-Aldrich GenomePlex WGA4 kit.  The diploid 
population DAPI fluorescence intensity was initially established with a lymphoblast diploid cell line 
(REFM)(42).   
Whole-genome amplification (WGA) was performed as described in the Sigma-Aldrich 
GenomePlex WGA4 kit (WGA4-50RXN).  The DNA concentration was measured (Thermo Fisher 
Scientific, Qubit 2.0 fluorometer), run on gel electrophoresis for size distributions, and sonicated to 
250 bp using the S220 Sonicater.  The products underwent NEB end repair and were subsequently 
purified with the DNA Clean and Concentrator-5 Kit.  The NEBNext DNA Library Prep enzymes 
were used for 3’ adenylation, adapter ligation, and PCR amplification to barcode each single-cell 
library with a P7 unique 8-bp identifier (NEXTflex-96 barcodes, Bio Scientific) and common P5 
adapter for sample multiplexing.  After adapter ligation, libraries were purified with AMPure XP 
beads 0.5x, and PCR-amplified (8-cycles).  Final library concentrations were measured by Qubit, and 
libraries were pooled in equimolar concentrations.  The final pooled library was quantified by 
quantitative PCR using the KAPA Library Quantification kit and the QuantStudio 6 Flex Real-Time 
PCR System.  Size distributions of the pooled submission were evaluated on 2100 Bioanalyzer 
(Agilent Technologies).  Pooled libraries were sequenced using 76 single-end or 76 paired-end cycles 
on the HiSeq2000 or HiSeq4000 (Illumina) at the Sequencing Core Facility of the Department of 
Genetics at MD Anderson Cancer Center.  
 
2.5 Sing l e -Ce l l  Copy Number  Data Analys i s  
Sequencing data was processed into a master FASTQ file using the CASAVA 1.8.1 pipeline 
(Illumina Inc.) and then demultiplexed using an in-house perl script(16) into individual FASTQ files 
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representing the sequencing reads from each single cell.  Sequence reads were aligned to the NCBI 
build 37 (HG19/NCBI37) using Bowtie2(134) and converted to sorted BAM files.  Poorly mapped 
reads (MQ<40) were filtered out using Samtools (0.1.19)(135).  PCR duplicates were identified as 
sequencing reads with the exact same starting position and were also removed from read counts via 
an in-house Python script.  Single cell copy numbers were calculated using the variable binning 
method followed by the Circular Binary Segmentation (CBS)(145) as previously described(12, 125). 
Sequencing reads were counted into 11,927 genomic bins with variable start and stop coordinates to 
simulate mapping bias across the genomic positions, where the median genomic length spanned by 
each bin is 220 kb. Loess normalization was used to correct for GC bias(125).  Copy number 
segmentation was performed using the CBS method(145) followed by MergeLevels(146) to join 
adjacent segments with non-significant differences in segment ratios. The parameters used for CBS 
segmentation was alpha=0.0001 and undo.prune=0.05 respectively. Default parameters were used 
for performing MergeLevels, which successfully joined false positive detections of erroneous 
chromosome breakpoints.  
 
2.6 Sing l e -Ce l l  Copy Number  Clona l  Dynamics  
Clonal subpopulations in single cell copy number data were defined using a hierarchical clustering 
method as previously described(16). The optimal number of clusters was determined by the average 
silhouette distance width. To construct the clustered heatmaps, the Euclidean distances were 
calculated from a segmented copy number data matrix where each column represented one single cell 
and each row contained the [log2(ratio+0.1)] transformed data of each segment. One-dimensional 
hierarchical clustering with ‘ward.D2’ linkage was performed in R using the heatmap.3 function from 
the ‘gplots’ package available on CRAN(147). Following identification of clonal subpopulations, the 
consensus copy number profile of each subpopulation was calculated by using the consensus ratio of 
each segment as the median ratios of all single cells within the subpopulation. Clonal lineage analysis 
was performed on aneuploid single cells that had genome-wide copy number aberrations. The 
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relative clonal frequencies of each subpopulations were calculated as the number cells that fell into 
each specific sub-clusters divided by the total number of clonal cells.  The tree structures of the 
clonal subpopulations was inferred using the neighbor-joining (NJ) tree method in the ‘ape’ 
package(148). Clonal lineages were then analyzed with TimeScape(149) using the NJ tree structures 
and the clonal frequencies across the treatment time points from the PROMIX trial. 
 
2 .7 Deve lopment  o f  Nove l  Next-Genera t ion Sequenc ing  Methods  
2.7.1 Preparation of Single-Nucleus Suspensions 
Nuclei from frozen tumors were isolated using a NST/DAPI buffer  (800 mL of NST [146 mM 
NaCl, 10 mM Tris base at pH 7.8, 1 mM CaCl2, 21 mM MgCl2, 0.05% BSA, 0.2% Nonidet P-40]), 
200 mL of 106 mM MgCl2, 10 mg of DAPI, and 5mM EDTA.  The frozen tumors were dissociated 
into nuclear suspensions by mincing with no.11 surgical scalpels in 1ml of NST-DAPI cytoplasmic 
lysis buffer at 4C using ice blocks in a plastic Petri dish.  Nuclear suspensions were filtered through 
37-µm plastic mesh filters (Falcon).  The final suspension was diluted to 1000 µL of 1 cell/50 nL 
with 1x PBS and D-RNase free water (0.35× PBS in the final dilution).  For the SKBR3 cell line, a 10 
cm cell plate at ~100% confluence was tryspinized and washed two times with 1x PBS.  The nuclei 
were released and stained with DAPI/NST lysis buffer, re-pelleted, suspended in DAPI-NST, and 
then filtered through a mesh filter.  As with the tumor single-nucleus suspension, the final 
suspension was diluted to 1000 µL of 1 cell/50 nL with 1x PBS and D-RNase free water. 
 
2.7.2 Preparation of Single-Cell Suspensions 
The single cell SK-BR-3 experiment was completed on the same day as the single-nucleus SK-BR-3 
experiment and used the same passage of cells.  A 50% confluent 10 cm plate of SKBR3 cells was 
trypsinized, washed two times with 1× PBS, filtered, and stained with Hoechst 33342 and propidium 
iodide (PI) to distinguish live/dead cells according to manufacturer’s recommendations  
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(ThermoFisher).  The whole-cell suspension was dispensed in the same manner as the nuclear 
suspension (Figure 4).  
 
2.7.3 Imaging QC of Nuclear and Cellular Suspensions 
To ensure that the nuclear fractions did not have any evidence of cytoplasmic membranes, we 
stained the nuclear fractions with Hoechst and Cytotracker Red for imaging at 40X on the Nikon 
Eclipse fluorescent microscope.  Similarly we stained cellular fractions with Hoechst and Cytotracker 
Red to image the cytoplasm and nucleus.  Z-stack images were collected in fluorescent channels, in 
Figure 4 – Microscopy of stained single whole cells and nuclei.  Purified suspensions of single cells 
and single nuclei from the MDA-MB436 breast cancer cell line were stained with DAPI (nuclei) or 
Hoechst (cells) and imaged using fluorescence and brightfield microscopy at 40X magnification.  
Although the majority of DAPI is excluded by the cell membrane in living cells, there is always a 
small amount that permeates and shows low-level staining of the nucleus of live cells.  However 
these levels are much lower compared to the DAPI staining in the isolated nuclei (right panels). 
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addition to brightfield imaging, and images were merged to observe the cytoplasm and nuclei of the 
cell suspensions. 
 
2.7.4 Nanogrid Single Cell/Nucleus Sequencing System 
The ICELL8™ single cell nanogrid RNA sequencing system consists of three main components:    
1) An ICELL8™ nanogrid chip manufactured in a square layout (72x72) in a 41 mm2 
aluminum alloy with 5184 nanoliter wells (150nl) using standard manufacturing 
processes(150).  Each nanowell was preprinted with barcoded primers (UMIs) with poly(dT) 
ends during manufacturing.  This chip-based technology has been published previously in 
targeted sequencing and real-time PCR applications(151, 152). 
2) A multisample nanodispenser (MSND) that uses microsolenoid-control to precisely dispense 
50 nL volumes into the nanowells.   
3) An automated imaging system composed of an Olympus BX43 microscope fitted with a 4x 
objective, a robotic stage and a CCD camera that is programmed to take images of all 5184 
wells using a customized version of µManager open source software, followed by automated 
image analysis software called CellSelect™ that is used to analyze acquired images and 
identify single-cell or nuclei containing wells.  
A more detailed technical description of the ICELL8 nanogrid single cell sequencing system and its 
hardware components is provided elsewhere(153).   
 
2.7.5 Nanodispensing of Nuclei and Cells 
Disaggregated nuclear or cellular suspensions were diluted to 20 cells/µl in eight wells of a 384-well 
plate (A1 through D2) and dispensed into the WaferGen ICELL8™ chip, resulting in a Poisson 
distribution with about 30% of nanowells with single nuclei or cells.  Poisson distribution of cells or 
nuclei in the chip nanowells was achieved because each 50 nL dispense on average dispensed a single 
cell when cells were at 20 cells/µl.  Addressing every well of the ICELL8 chip took 12-15 min.  
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Every nano-well contained an adapter sequence with a well Barcode (WB, 11nt), Unique Molecular 
Identifier(43) (UMI, 10nt) and a 30-mer oligo-dT that was subsequently incorporated into the 3’ end 
of the transcript during whole-transcriptome-amplification (WTA) using the Smart-Seq2(111) 
chemistry.   
 
2.7.6 Nanowell Imaging and Selection of Single Nuclei and Cells 
Following cell dispensing, the microchip was centrifuged to collect cells in a single plane and the 
nanogrid wells were automatically imaged using an Olympus BX43 fluorescent microscope with a 
robotic stage.  The image acquisition took about 6 min (3 min per fluorphore).  After imaging, the 
microchip was sealed, placed in freezing chambers, and stored at -80°C until reverse-transcription 
(RT).  Custom CellSelectTM software identified wells with single cells and filtered cells with no cells or 
multiple cells based on multiple automatic and user-adjustable imaging parameters.  The nanowells 
with single cells or nuclei were then prioritized and the user could manually review images and 
fluorescent channels to identify live cells or nuclei for selection.  A file containing positional 
information on identified candidate wells (dispense file) instructed the nanodispensor to deposit 
reagents only in the selected wells for WTA.   
 
2.7.7 3’ Reverse Transcription and PCR Amplification 
Two versions of the RT chemistry were used in the study.  Version 1 was used for method 
development, wherein frozen chips were thawed, and 50nL of RT solution (88µL 5x RT buffer, 
44µL 10mM RT dNTPs, 4.4µL 100 µM RT E5OLIGO, 57.2µL D-RNase-free water, and 26.4µL 
200 U/µL RT enzyme) was deposited into each selected well via the nanodepositing system.  For 
chips with single nuclei, the 57.2µL D-RNase-free water was replaced with 52.8µL D-RNase-free 
water and 4.4µL Triton X-100 to promote lysis of the cellular membrane.  After RT, cDNA products 
from selected wells were pooled together, purified, and underwent exonuclease I treatment (2µL 10× 
exonuclease buffer, 1µL 20 U/µL exonuclease I) to remove excess, unannealed primers. The pooled 
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barcoded cDNA libraries then underwent PCR amplification (5µL 10× amplification buffer, 1µL 50x 
amplification dNTPs, 1µL amplification primer, 1µL amplification enzyme, 22µL D-RNAse-free 
water) for 18 cycles for cells or 19 cycles for nuclei.  The PCR products were purified with 0.6× 
AMPure XP beads and eluted in 12µL D-RNase-free water.  The size distribution of cDNA was 
QCed using the Qubit dsDNA HS Fluorometric Assay and Agilent’s High Sensitivity DNA Chip on 
the Bioanalyzer system.   
Version 2 was used for the longitudinal TNBC samples from the PROMIX trial.  Frozen 
chips were thawed, and 50nL of RT solution (56µL 5M betaine, 24µL 25 mM dNTP mix, 3.2µL 1 M 
MgCl2, 8.8µL 100 mM DTT, 61.9µL 5X SMARTScribeTM First-Strand Buffer, 33.3µL 2X SeqAmpTM 
PCR Buffer, 4.0µL 100µm RT E5OLIGO, 8.8µL 10µM Amp Primer, 1.6µL 100% Triton X-100, 
28.8µL SMARTScribeTM Reverse Transcriptase, and 9.6µL SeqAmpTM DNA Polymerase) was 
deposited into each selected well.  After RT, complementary DNA (cDNA) products from selected 
wells were pooled together, purified, and underwent PCR amplification.   The amplified product was 
purified with 0.5x AMPure XP beads and eluted in 11µL D-RNase-free water.  Eluted product was 
quantified with Qubit dsDNA HS Fluorometric Assay and Agilent’s High Sensitivity DNA Chip.   
 
2.7.8 Library Construction and Next-Generation Sequencing 
The pooled cDNA was diluted to 0.2 ng/µL and used to construct Nextera XT (Illumina) DNA 
libraries with i7 index primers following manufacturers instructions.  The final libraries, containing 
barcoded single-nuclei or single-cell transcriptomes, were sequenced at 100 paired-end cycles on the 
HiSeq4000 system (Illumina).  Data was processed using the CASAVA 1.8.1 pipeline (Illumina Inc.), 
and sequence reads were converted to a master FASTQ files.  
 
2.7.9 Bulk RNA Sequencing of Nuclei and Cells 
Bulk RNA sequencing was used to compare the transcriptional profiles of nuclear and whole-cell 
populations.  RNA was extracted from nuclear and cell fractions isolated from four breast cancer cell 
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lines (MDA-MB-436, BT-549, MDA-MB-231, T47D).  One 10 cm dish at 60-85% confluence was 
used for each biological replicate (three biological replicates per cell line) and was washed with 9mL 
of 1x PBS (-/- for calcium and magnesium).  Cells were then resuspended in 1 mL trypsin and 9 mL 
cold PBS (1x, -/-).  60µL of the trypsinized cells were set aside to prepare slides for whole-cell 
imaging and microscopy.  The remainder of the cells was spun at 200 rcf for 5 minutes.  The 
supernatant was subsequently removed, and  the cells were resuspended again in 2 mL PBS (1x, -/-).  
One mL of the PBS cellular suspension was removed for whole-cell RNA extraction, spun at 100 rcf 
for 5 minutes at 4C, and resuspended in 2 mL trizol.  A 20G needle was used to break apart the 
insoluble trizol pellets, and whole-cell RNA extraction was performed according the manufacturer’s 
instructions (Fisher TR 118-100ML).  The other mL of the PBS cellular suspension was removed for 
nuclear RNA extraction, spun at 100 rcf for 5 minutes at 4°C, and resuspended in 1 mL DAPI/NST 
with EDTA.  The DAPI/NST solution was incubated at room temperature for 4 minutes, spun at 
8000 rcf for 5 min at 4C, and resuspended in 1 mL DAPI/NST.  After a final spin at 8000 rcf for 5 
min at 4C, the nuclei were resuspended in 1 mL trizol.  A 20G needle was used to break apart the 
nuclear pellet, and an additional 1 mL of trizol was added to the suspension.  Nuclear RNA 
extraction was performed according the manufacturer’s instructions (Fisher TR 118-100ML).   
 
2.8 RNA Sequenc ing  Data Analys i s  
2.8.1 RNAseq QC and Data Processing 
The master FASTQ file containing total reads was demultiplexed into individual FASTQ files with 
each representing one single cell or one population of cells using a Perl script (Figure 5a).  
Sequencing reads in each single FASTQ files were mapped to the human transcriptome using 
bowtie2(154), and gene expression levels were summarized into expected count and transcripts per  
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kilobase million (TPM) values using RSEM(155).  Only uniquely mapped reads were used for 
analysis.  A quality control step was performed on the tophat2(156)-aligned BAM files using 
RSeQC(157) and Samtools (0.1.19)(135)  to summarize distributions of reads that were mapped to 
ribosomal RNA (rRNA), mitochondrial RNA (mtRNA), introns, coding sequence (CDS), 5’UTR, 
3’UTR and 10 kb up-/down-stream of transcripts (Figure 5b).  The number of UMIs for each gene 
was counted by dropping reads that had duplicated UMIs using custom Perl scripts.  However, we 
did not include UMI assays in this study.  
 
Figure 5 - Data processing and analysis workflow for single whole cell and single nuclei.  (a) 
Sequence reads are demultiplexed by well barcodes (WBC) and aligned to the human genome 
reference assembly. (b) Quality control metrics are calculated and read counts are normalized by 
library size and housekeeping genes, transformed to z-scores or TPM using RSEM. (c) Differentially 
expressed genes are identified using SCDE and annotated for gene ontologies and pathways. (d) 
Clustering and multivariate analysis is performed to identify groups of cells with similar 
transcriptional profiles. (e) Copy number profiles are calculated from RNA profiles. (f) Gene 
signature analysis and classification of breast cancer subtypes is performed. 
a
 
b c d 
e 
f 
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2.8.2 Differential Gene Expression Analysis 
We compared the gene expression in single nuclei to whole cells using a Bayesian method for single-
cell differential expression (SCDE)(158) analysis, which fits individual error models for single cell 
RNAseq data using a Bayesian approach based on a zero-inflated negative binomial model process 
(Figure 5c).  The differentially expressed genes were defined as false discovery rate (FDR) adjusted p-
value < 0.05 and |log2(fold change)| >=1.  We removed genes that were detected with counts <10 
in less than 30 cells.  We applied an Empirical Bayes hierarchical model (EBSeq)(159) for population 
RNAseq differential expression analysis at gene levels.  The differentially expressed genes were 
defined as those had Posterior Probability of being DE (PPDE) > 0.95 and |log2(fold change)| 
>=1.  Clustered heatmaps of gene expression were generated with R package ‘heatmap3’(17) based 
on log2(count+1), log2(TPM+1) or z-scores (Figure 5d).  Differentially expressed genes were 
analyzed with Ingenuity IPA for pathway analysis and cellular organelle localization annotations.  To 
identify differentially expressed cancer genes in TNBC tumor cells, we combined the three 
subpopulations of single nuclei that had aneuploid CNA profiles as tumor cell populations and 
combined the predicted matched normal nuclei and normal nuclei from another patient as the 
normal cell populations.  We then performed differential gene expression analyses between the two 
groups of single nuclei using MAST(160, 161).  The differential genes were defined as having FDR 
adjusted p-value < 0.05 and |log2 (fold change)| ≥1.  Finally, differentially expressed cancer genes in 
tumor cells were identified by intersecting the DE gene list with a T200 clinical gene panel and with a 
40-gene TCGA breast cancer gene list. 
 
2.8.3 Breast Cancer Subtype Prediction 
We used the intrinsic gene centroids signature (PAM50)(162) to classify single cells and nuclei into 5 
established intrinsic breast cancer molecular subtypes (normal-like, basal, luminal A, luminal B and 
Her2 amplification) using ‘genefu’ package(163) with log2(TPM+1) data matrix.  Single cells or 
nuclei with low prediction confidence (< 0.7) are set as undefined.  In a separate analysis, single 
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nuclei were classified into 6 TNBC subtypes including 2 basal-like (BL1 and BL2), an 
immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem–like (MSL), and a luminal 
androgen receptor (LAR) subtype(11).  The ER+ cells were excluded from TNBC subtype 
prediction (Figure 5f). 
 
2.8.4 Gene Set Variation Analysis 
We applied single-sample gene set variation analysis (ssGSVA)(164) to determine the molecular 
phenotypes of single cells and nuclei using log2(TPM+1) data (Figure 5f).  We first obtained GSVA 
scores for 189 oncogenic gene sets (MSiDB version 5.2)(165) for each single nuclei or whole-cell 
sample, and then compare the nuclei enrichment scores to whole cells by using the R package 
‘limma’(166).  Differentially enriched gene sets were defined as FDR adjusted p-value < 0.05 and 
|score difference|>= 0.1.  
 
2.8.5 Cell Cycle Analysis of Single Nuclei 
Cell cycle genes from the gene ontology set (version 5.2 MSiDB)(167-169) with annotations of “G1 
phase of mitotic cell cycle” for G1 phase genes, “S phase of mitotic cell cycle” for S phase genes, “M 
phase of mitotic cell cycle” for M phase genes were used.  A G2 phase gene list that was previously 
defined in synchronized HeLa cells was also used(170).  We then defined the four cell phase (G1, S, 
G2, M) scores as the average expression [log2(TPM + 1)] of curated cell cycle genes and defined the 
cell cycle phase by hierarchical clustering of centered phase scores using R package ‘heatmap3’(17). 
 
2.8.6 High-Dimensional Reduction Data Analysis 
The normalized log2(count+1) matrix was centered and scaled to z-scores to perform principle 
component analyses (PCA) using the ‘prcomp’ function in R (www.r-project.org).  Genes that were 
detected in fewer than 30 cells were excluded from the analysis.  The first 5 components were 
selected based on ‘elbow’ principle and the top 20 loading genes were sent for clustering using a 
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shared nearest neighbor (SNN) modularity optimization based method(171).  Then, marker genes for 
each detected cluster were selected using the normalized log2(count+1) matrix with the ‘bimodal’ 
based gene expression analysis(172) that was built in the ‘FindAllMarkers’ function in the R package 
‘Seurat’(173).  The t-distribution Stochastic Neighbor Embedding (t-SNE)(174) method was applied 
based on the pair-wise Euclidean distances of the log2(count+1) matrix. Hierarchical clustering with 
‘ward.D2’ linkage and ‘Euclidean’ distance was performed on log2(count+1) matrix or z-scores using 
R package ‘heatmap3’(17). 
 
2.8.7 Copy Number Calculation from Single-Cell RNA Data 
Single-cell and nucleus copy number was calculated from the log2(TPM+1) matrix using a ‘moving 
average’ approach that was adapted from a previous study(47) (Figure 5e).  We used the 
log2(TPM+1) values as gene expression values and we further scaled the total expression of all cells 
to 100,000 to normalize gene expression within each single cell to comparable scales and to avoid 
floating the variance among highly expressed genes.  We sorted the analyzed genes by their genomic 
coordinates, which were annotated by a UCSC gene list containing a total of 23,346 genes.  We 
excluded genes that had expression values < 0.15 on average, and ended up with ~3000 genes across 
the genome and ~130 genes per chromosome on average (except the Y chromosome, which had 
only one or two genes).  To define the copy number baseline, we also sequenced a set of 380 normal 
breast tissue single cells, and took their average expression of each gene as the normal copy number 
base line.  We normalized single-cell gene expression to this baseline in order to obtain a relative gene 
expression for each gene location.  To mitigate the bias caused by extreme gene expression levels, we 
replaced the relative gene expression values that were > 3 with 3 and relative expressions that were < 
-3 with -3.  We then obtained a ‘moving average’ of adjacent 50-gene relative expression values to 
represent the log2(copy number ratio) of the genomic location.  We normalized the log2(copy number 
ratio) to their mean values for each cell to center around zeros.  Lastly, we performed hierarchical 
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clustering(17) of all tested single cell CNAs with the normal breast tissue cells to identify aneuploid 
tumor and normal diploid cell populations. 
 
2.8.8 Normal Cell Type Prediction from Single-Nucleus RNA Data 
Prediction of known normal cell types in the clonal extinction post-treatment tumors was performed 
using a semi-supervised approach. We first classified immune cell types using established markers: T 
cells (CD4|CD8A|CD8B), B cells (CD19|CD20) or other immune cells (CD45).  For the remaining 
cell types we performed a decision tree using Gini coefficients to evaluate the variability of known 
cell type markers across all the remaining cells. Larger Gini coefficients indicated stronger 
unevenness of the marker gene expression across the remaining cell populations, and therefore the 
cell type with the largest Gini coefficient was determined first. The remaining cell types with smaller 
coefficients were identified subsequently in an iterative process. The markers for the remaining cell 
type classification in sequential included: fibroblasts (ACTA|CAV1|FAP|FN1), luminal epithelial 
cells (CK8|CK18), adipocytes (ADIPOR1/2), basal epithelial cells (CK5|CK14) and endothelial 
cells (PECAM1|CD34).  We used the gene expression [log(TPM/10+1)] cutoff=1 to determine 
whether a cell marker was expressed in a single cell.  In our datasets, we observed a subset of cells 
that were co-expressed both fibroblasts and epithelial cells markers. Since ‘fibroblast’ cells were 
defined before epithelial cells, we reclassified certain ‘fibroblast’ cells as epithelial cells if they 
expressed higher levels of epithelial markers on average.  
 
2.8.9 Survival Analysis in Extended Patient Cohorts  
To determine whether the chemoresistance-associated gene signatures were associated with patient 
survival, we obtained the METABRIC dataset (175, 176) with mRNA gene microarray expression 
data and long term clinical follow-up data. We analyzed a total of N=412 breast cancer patients that 
received chemotherapy. To test the association of selected gene sets with patient survival, we first 
performed gene set variation analysis (164) and stratified patients into low enrichment (ssGSVA 
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score ≤ -0.1) and high enrichment (ssGSVA core ≥ 0.1) groups.  We then performed a Cox 
proportional hazard regression of survival month and survival status over gene set enrichment status 
using the R ‘survival’ package (Therneau 2015) and the log-rank test p-values were used to determine 
significance. 
 
2.9.0 Integration of Single-Cell Copy Number Data with SNV Mutations 
To integrate single cell copy number with the bulk mutation data, we used Samtools (0.1.19) (135) to 
perform ‘mpileup’ of sparse single cell copy number reads and quantified the number of variant reads 
at specific mutation sites that were detected by exome sequencing.  Mutation sites with ≥ 1 variant 
read counts in at least one cell were called as mutated sites. Mutations in single cells were then 
mapped to clonal subpopulations in maximum parsimony trees constructed from the single cell copy 
number data. With this approach, a subset of clonal mutations were successfully mapped to the 
truncal lineages of the copy number trees, however the limited coverage at subclonal mutation sites 
did not permit accurate mapping to the subclonal lineages. 
  
2.9.1 Integration of DNA Mutations and RNA Single-Cell Data 
Since the single nuclei RNA expression data had coverage only at the 3’ ends, we mapped all exome 
mutation sites to the last exons of genes to identify a subset of mutations with these criteria.  We 
used Samtools (0.1.19) (135) ‘mpileup’ to obtain sparse 3’ single cell RNA sequencing read counts for 
mutations detected in the last exons of genes.  Mutation sites with ≥ 1 read count coverage in the 
RNA data that matched the mutation variant base were considered as positive for having the 
expressed mutation, while sites with ≥ 1 read count coverage and only reference bases were 
considered as negative for the expressed mutation.  Sites with no read count data in samples were 
indicated as ‘low coverage’ for detecting the expressed mutation.   
 
2.9.2 Identification of Primed Cells by Integrating Single-Cell CNA and RNA Data 
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We identified ‘primed’ cells in the pre-treatment tumor samples that expressed a subset of the 
chemoresistant genes by integration of single cell CNA data with single cell RNA data.  Due to the 
sparseness of the single cell RNA data, we performed imputation using Single Cell Analysis Via 
Expression Recovery (SAVER) (177) to improve copy number estimations. Next, we identified the 
CNAs associated with resistance in the single cell DNA copy number profiles that expanded in the 
resistant clones from the persistence patients.  To find the pre-existing single cells that had resistant 
CNA genotypes, we clustered all pre-treatment single cells with post-treatment single cells using 
hierarchical clustering with the calculated RNA copy number profiles. Single cells with resistance 
associated CNAs that clustered together were defined as having a resistant genotype, whereas pre-
treatment single cells that did not have resistance associated CNAs were defined as having a sensitive 
genotype.  We next obtained a restricted list of significant top variable genes (N<50 genes) by 
comparing the transcriptional profiles of the post-treatment resistant cells (those that had both 
resistant genotypes and phenotypes) to pre-treatment nonresistant cells (those that did not have 
resistant genotypes or phenotypes) using MAST (FDR adjusted p < 0.05; |log2(fold change)| ≥ 
1.58) (160).  Next, we performed random forest regression with the R ‘randomForest’ package (178) 
on 70% of the data using the top variable genes followed by prediction of resistance/sensitive 
classification for all single cells within each tumor. We defined the predicted probability of classifying 
a resistant single cell to be the resistance expression score of each cell. To determine the cutoff of the 
resistance expression score and define the primed cells, we calculated the cutoff score that separated 
pre-treatment cells within each tumor into two groups using the least square method and took the 
median values across the 4 patients as the universal cutoff (cutoff=0.172).  We manually set the 
resistance cutoff as 0.6 to account for RNA dropout noise in the single cell RNA data.  As such, 
single cells that had a resistance expression score >=0.6 were defined as resistant cells, and single 
cells that had resistance expression scores between 0.172 and 0.6 were defined as primed cells.   
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CHAPTER 3: NANOGRID SINGLE-NUCLEUS RNA SEQUENCING REVEALS 
PHENOTYPIC DIVERSITY IN BREAST CANCER 	
[Note: This chapter is based on published material from Gao and Kim et al. 2017 (Gao, R and Kim, 
C. et al. Nanogrid Single-Nucleus RNA Sequencing Reveals Phenotypic Diversity in Breast Cancer 
Nat Commun 8, doi:doi:10.1038/s41467-017-00244-w, 2017).  Nat Commun articles are published 
under a CC BY license (Creative Commons Attribution 4.0 International License), which establishes 
that authors retain copyright in their articles.] 	
3.1 Introduc t ion  and Rat iona le   
Single-cell RNA sequencing has provided new insights into cancer progression by resolving complex 
cell types(42, 47, 179), developmental hierarchies(42, 47, 180) and phenotypic plasticity(44, 46).   
However, initial methods were limited by low-throughput, high costs and extensive technical errors, 
which inhibited their broad application in cancer research(128, 181, 182).  Recent technological 
innovations using microwells(108, 183, 184) and microdroplet encapsulation(110, 112) have increased 
the throughput of single cell RNAseq to thousands of cells and greatly reduced associated costs.  
However, high-throughput methods do not enable imaging or selection of single cells, leading to high 
doublet error rates and the inclusion of many unwanted cells, such as dead cells(128).  Furthermore, 
the ability to sequence RNA in nuclei instead of whole cells on these platforms has not been 
demonstrated. 
A second major challenge for single-cell RNA sequencing in cancer research is that most 
methods require fresh tissue to be dissociated into single cell suspensions for analysis(185).  This is 
logistically challenging and problematic in cancer research, because the majority of archival tissue 
samples have previously been flash-frozen and stored in cryobanks, a process that ruptures the cell 
membranes.  Nevertheless, previous work has shown that nuclear membranes remain intact during 
freeze-thaw cycles, and that single nuclei can be isolated from frozen tissues(186), consequently 
permitting the preparation of nuclear suspensions(12, 17, 18) and construction of nuclear cDNA 
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libraries.  Neuroscientists have also shown that RNA sequencing of single nuclei is feasible and 
highly representative of transcriptional profiles from cells, when fresh tissues are dissociated(109, 
186-188) and even when postmortem brain tissue stored long-term at -80ºC is used(186).  This is in 
contrast to whole brain cells, where use of proteases for whole cell dissociation has been shown to 
activate the crucial immediate early genes(189) and confound RNAseq results.  However, to date, no 
one has investigated the transcriptional profiles of single tumor nuclei, to determine if they are 
representative of whole tumor cells.    
To address these limitations, we developed a novel nanogrid platform and microfluidic 
depositing system that enables imaging, selection and sequencing of thousands of single cells or 
nuclei in parallel.  We applied this nanogrid single-nucleus RNA sequencing (SNRS) system to 
compare the transcriptional profiles of cancer cells and nuclei in cell lines and further applied this 
method to study phenotypic diversity and subpopulations in a frozen tumor sample from a TNBC 
patient.  We subsequently used this system to evaluate the phenotypic evolution of TNBC in 
response to chemotherapy. 
 
3.2 Resu l t s  
3.2.1 Concordance of Bulk Nuclei and Cells from Cell Lines 
Prior to single cell analysis, we investigated whether the transcriptional profiles of bulk cells and  
nuclear fractions are concordant in breast cancer cell lines.  We performed RNAseq of nuclear and 
cellular fractions isolated from millions of cells from 4 breast cancer cell lines, including three triple- 
negative subtypes (BT549, MDA-MB231, MDA-MB-436) and an ER+/PR+ subtype (T47D). 
Nuclear fractions were purified from cellular suspensions using a detergent to lyse the plasma 
membrane, followed by three rounds of purification to eliminate residual cytoplasmic RNA. The 
nuclear suspensions were imaged in bright field and fluorescence using DAPI to ensure that the 
cellular membrane and cytoplasm were no longer present. RNAseq was performed on the nuclear 
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and cellular fractions from each cell line at 20 million reads per sample, resulting in 50% of the reads 
Figure 6 – Bulk sequencing metrics of whole cells versus nuclei. (a) Scatter plots of gene expression 
[log2(counts+1)] from bulk cellular and nuclear fractions isolated from four breast cancer cell lines.  
Significant differentially expressed genes are highlighted in red and Pearson correlations are 
indicated. (b) Gene expression heatmap of 40 breast cancer genes identified in TCGA across three 
biological replicates of bulk cell and nuclei factions from the four breast cancer cell lines. 	
a 
b 
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mapping to the CDS regions and 15-16K gene coverage for each cell line.  Correlations in gene 
expression levels between the nuclear and cellular suspensions were very high (rs  > 0.9), with only 3-
38 discordant genes in each sample (Figure 6a).  In total, BT549 showed 13/15699 discordant genes, 
while MDA-MB231 showed only 3/15592 discordant genes, MDA-MB436 showed 4/16479 
discordant genes, and T47D showed 6/16314 discordant genes between cells and nuclei.  
Importantly, most genes had differences in expression levels, rather than having a complete absence 
of expression in the cells or nuclei.  However, EIF3CL was only detected in BT549 whole cells, and 
was not detected in the nuclei. We speculate that is the result of rapid transportation between cellular 
compartments, since the sequencing depth was sufficiently high in both samples to rule out false-
negatives. Notably, 6 differentially expressed genes were read-through transcripts (Figure 6a).   
We also examined the gene expression levels for a targeted set of 40 breast cancer genes that were 
previously reported to be frequently deregulated in TCGA(13).  These data showed only minor 
variations between cells and nuclei that were not statistically significant (FDR adjusted p-value >= 
0.05 or |log2(fold change)| < 1) across three biological replicates in each of the 4 cell lines (Figure 
6b).  Collectively, these experiments suggested that the transcriptional profiles of bulk nuclear RNA 
are highly representative of cellular RNA in breast cancer cell lines. 
 
 
3.2.2 Nanogrid Single Nucleus RNA Sequencing Method 
 
We developed a high-throughput nanogrid single nucleus RNA sequencing (SNRS) approach called 
the ICELL8 system (Wafergen, Inc) (Figure 7).  The nanogrid system consists of three main 
components: 1) an alloy nanogrid with 5184 nanowells, 2) a nanodispensing system and 3) an 
automated imaging system.  First, single cell or single nucleus suspensions are prepared from cell 
lines or frozen tissues and stained with propidium iodide (PI) and Hoechst (cells) or stained with 
DAPI (nuclei).  The suspensions are then diluted to 1 cell or nucleus per 50nL and dispensed into the  
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nanogrid resulting in a Poisson distribution of cell occupancies across the 5184 nanowells with 
~1800 wells that are expected to have single cells or nuclei (Figure 7a, Figure 8).  Each well in the  
nanogrid has a unique 11bp pre-printed well barcode (WBC) that also contains an oligo dT sequence, 
a 10bp unique molecular identifier (UMI) and a P5 Illumina adapter sequence.  After the cells or  
Figure 7 – Wafergen sequencing pipeline.  (a) Nuclear or cellular suspensions are prepared and 
stained with DAPI (nuclei) or Hoechst and Propidium Iodide (cells) for nanodispensing into the 
5184 wells in the nanogrid.  Each nanowell is 400-600 µm, and the well depth range is 950 µm – 2.2 
mm.  (b) The nanowells are imaged using automated scanning fluorescent microscopy and 
approximately 1800 wells containing single nuclei or cells are selected, while nanowells containing 
multiple cells, no cells or dead cells are excluded. (c) In the selected nanowells, the nanodispensor 
deposits lysis buffer and WTA reagents to perform reverse transcription of mRNA to cDNA using 
SCRB-Seq chemistry. This process also adds a UMI, well barcode and P5 adapter sequence to the 
(A)n tail.  N represents A, C, G, or T; B represents C, G, or T; and V represents A, C, or G. (d) The 
barcoded cDNA with adapter sequences is pooled into a single reaction.  (e) Nextera tagmentation is 
performed followed by PCR amplification to generate sequencing libraries with Illumina I7 indexes. 
(f) Next-generation sequencing is performed on the pooled libraries, after which the individual cell 
data is demultiplexed using the well barcodes 
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nuclei are dispensed, automated imaging is performed within 10 minutes using a fluorescent  
microscope with a robotic stage to image all 5184 wells (Figure 7b).  The software automatically  
identifies nanowells containing single cells or nuclei and excludes wells with doublets or no cells.  
The user can then choose to manually select a subset of the prioritized cells based on the 
morphology parameters, PI, Hoechst or DAPI staining.  Only wells with live cells (PI -, Hoechst +) 
Figure 8 – Sequencing library structure of Wafergen libraries.  3’ Single cell RNA sequencing is 
performed by hybridization of the polyA mRNA tail to an oligo dT30 adapter with a 11bp well 
barcode and 10bp UMI that is pre-printed in each nanowell.  Single cells or nuclei undergo reverse-
transcription using template switching and extension, followed by full-length cDNA amplification.  A 
one-sided tagmentation reaction is then used to add a Nextera transposase adapter to the 5’ end (the 
other strand is omitted for illustrative purposes).  PCR is performed using the nextera P5 primer and 
i7 index primer to extend the adapter sequences and enrich the library concentrations.  The final 
sequencing reaction involves 3 sequencing primers to read the WBC and UMI (read1), the 3’ RNA 
sequence (read 2) and the i7 nextera sample index (read3).  In this figure N represents A, C, G, or T; 
B represents C, G, or T; and V represents A, C, or G. Dotted lines indicate where the first nucleotide 
hybridizations occur.  
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or intact nuclei (DAPI+) are selected for depositing reagents for lysis and whole-transcriptome-
amplification (WTA) (Figure 7b).  The WTA reaction is performed using SCRB-Seq(190), which uses 
template-switching to select polyadenylated RNA and incorporate a P5 adapter sequence along with 
the WBC and UMI into the 3’ end of each RNA molecule (Figure 7c).  A second adapter is added to 
the 5’ end (RT-E5OLIGO) by template switching for second strand synthesis and subsequent PCR 
enrichment.  The nanogrid is then inverted and all of the barcoded cell libraries are pooled together 
into a single reaction for PCR amplification followed by QC for size distributions (Figure 7d).   The 
cDNA is then used to generate Illumina sequencing libraries with one-sided tagmentation and PCR 
amplification (Figure 7e).  The pooled libraries are sequenced on the Illumina system, and individual 
FASTQ files are demultiplexed using the WBC identifiers for downstream data processing and  
analysis (Figure 7f).  
 
 
 
3.2.3 Single Nuclei and Cell Concordance in a Cancer Cell Line 
To determine if the transcriptional profiles of single nuclei were representative of whole-cells, we 
applied nanogrid SNRS to isolate and sequence nuclei and cells from an isogenic Her2+ breast 
cancer cell line (SK-BR-3) (Figure 9).  Nuclear and cellular suspensions were prepared and stained 
with a nuclear stain (Hoechst) and cytoplasmic stain (cytotracker) to confirm that the cytoplasmic 
membrane was no longer intact in the nuclear suspensions (Figure 9a).  We subsequently stained the 
nuclear suspensions with DAPI and the cellular suspensions with PI and Hoechst and dispensed 
single cells into the nanogrid for automated imaging (Figure 9b).  In total, we selected 525 single 
nuclei and 525 live cells in the nanogrids for sequencing (Figure 9c).  
To understand global expression differences in the data, we computed a number of metrics 
for the single cell and nuclei datasets (Figure 9d).  On average, we sequenced 1.3 million reads per 
nucleus or cell, achieving a coverage of 4600-5500 genes and average unique molecular index (UMI) 
count of 34,690 (±12,609 S.D.) for cells and 34,540 (± 10,570 S.D.) for nuclei.  Single cells or nuclei  
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with poor metrics were filtered, resulting in final datasets of 485 nuclei and 424 whole cells. Although 
the difference in variance for most distributions was determined to be significant by Kolmogorov-
Smirnov test (P < 0.05) due to large numbers of nuclei in each distribution, most metrics, including 
mapped read fractions, 5’ UTR tags, 3’ UTR tags, rRNA reads and gene coverage showed very low 
percent changes (2-5%) between nuclei and cells.  However, we did observe an 8.5% increase in 
Figure 9 – Microscopy, nanowell selection, and metrics for single whole cells and nuclei.  (a) Nuclear 
suspensions were stained with DAPI (blue) and cytotracker (red), while cellular suspensions were 
stained with Hoechst (blue) and cytotracker (red) for fluorescent microscopic imaging at 40X 
magnification to visualize the nucleus and cytoplasm. (b) Nanodispensed nuclei and cells were 
imaged in nanowells using DAPI, or Hoechst and PI (c) Nanogrid maps of cells or nuclei that were 
selected for RNA sequencing. (d) Sequence data metrics were calculated for single nuclei and single 
cells from the SK-BR-3 breast cancer cell line. 
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intron tags and 9.2% decrease in CDS tags in the single nuclei data, which is consistent with the 
dogma that nuclei contain unprocessed pre-mRNA that have not yet undergone splicing and export 
from the nucleus(191, 192).  To compare our data to another platform, we performed Drop-Seq 
analysis of SK-BR-3 cells and compared the sequencing metrics to downsampled Nanogrid RNA 
data (Table 1).  These data revealed similar per cell gene detection rates but higher UMI counts per 
cell on the Nanogrid platform. 
 
 
  
Platforms Drop-seq Nanogrid*
median total reads per cell 90,732 90,732
number of cells sequenced 8,128 525
median mapping rates per cell 29.00% 68.72%
median mapped reads per cell 26,312 62,354
median CDS reads/tags fractions 30.60% 72.26%
median Intron reads/tags fractions 6.00% 1.33%
median gene covered per cell 2,714 2,349
median UMIs per cell 16,414 25,061
Supplementary Table 3- Comparison of Sequencing Metrics of Nanogrid 
SNRS to Drop-seq 
*data were downsampled from original sequenced fastq files.
Table 1 - Sequencing and QC metrics for single cells that were profiled by nanogrid SNRS and 
Drop-seq from the SK-BR-3 cell line.  To perform a fair comparison the Nanogrid data was 
downsampled to 90,732 reads per cell before metrics were calculated.  
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Gene$ID FoldChange Entrez$Gene$Name cellular$localization gene$class
ANKRD20A9P 2.0 ankyrin1repeat1domain1201family1member1A9,1pseudogene Other other
ARHGEF26FAS1 2.8 ARHGEF261antisense1RNA11 Other other
ATP6V0A2 2.8 ATPase1H+1transporting1V01subunit1a2 Cytoplasm transporter
BRIP1 2.1 BRCA11interacting1protein1CFterminal1helicase11 Nucleus enzyme
C12orf65 2.2 chromosome1121open1reading1frame165 Other other
C21orf62 2.8 chromosome1211open1reading1frame162 Other other
CA5B 2.6 carbonic1anhydrase15B Cytoplasm enzyme
CBFA2T2 2.7 CBFA2/RUNX11translocation1partner12 Nucleus transcription1regulator
CCDC142 2.2 coiledFcoil1domain1containing1142 Other other
CEACAM22P 3.2 carcinoembryonic1antigen1related1cell1adhesion1molecule122,1pseudogene Other other
CEP104 2.1 centrosomal1protein1104 Cytoplasm other
CMBL 2.4 carboxymethylenebutenolidase1homolog1(Pseudomonas) Cytoplasm enzyme
CNNM3 2.6 cyclin1and1CBS1domain1divalent1metal1cation1transport1mediator13 Other other
CRX 2.1 coneFrod1homeobox Nucleus transcription1regulator
CYP4V2 2.8 cytochrome1P4501family141subfamily1V1member12 Cytoplasm enzyme
DCAF10 2.0 DDB11and1CUL41associated1factor110 Other other
DCUN1D2 2.0 defective1in1cullin1neddylation111domain1containing12 Other other
FAM116A 2.2 DENN1domain1containing16A Cytoplasm other
DFFB 2.3 DNA1fragmentation1factor1subunit1beta Nucleus enzyme
DMC1 3.2 DNA1meiotic1recombinase11 Nucleus enzyme
ENTPD4 2.4 ectonucleoside1triphosphate1diphosphohydrolase14 Cytoplasm enzyme
EPHA10 3.1 EPH1receptor1A10 Plasma1Membrane transmembrane1receptor
ERVVF1 2.8 endogenous1retrovirus1group1V1member11 Other other
EXD1 2.7 exonuclease13'F5'1domain1containing11 Other other
FAM126B 2.5 family1with1sequence1similarity11261member1B Other other
FAM74A1 2.9 family1with1sequence1similarity1741member1A1 Other other
FBLIM1 2.1 filamin1binding1LIM1protein11 Plasma1Membrane other
FBXO27 2.4 FFbox1protein127 Other other
FLJ42102 2.5 uncharacterized1LOC399923 Other other
FMN1 2.1 formin11 Nucleus other
GFOD2 3.0 glucoseFfructose1oxidoreductase1domain1containing12 Extracellular1Space enzyme
GGA2 2.0 golgi1associated,1gamma1adaptin1ear1containing,1ARF1binding1protein12 Cytoplasm transporter
GNE 2.5 glucosamine1(UDPFNFacetyl)F2Fepimerase/NFacetylmannosamine1kinase Cytoplasm kinase
GREB1 2.4 growth1regulation1by1estrogen1in1breast1cancer11 Cytoplasm other
GRIPAP1 2.3 GRIP11associated1protein11 Plasma1Membrane other
HNRNPA1P10 3.1 heterogeneous1nuclear1ribonucleoprotein1A11pseudogene110 Other other
IGF2R 2.1 insulin1like1growth1factor121receptor Plasma1Membrane transmembrane1receptor
IL17RD 2.4 interleukin1171receptor1D Cytoplasm other
IRF1 2.5 interferon1regulatory1factor11 Nucleus transcription1regulator
KBTBD12 2.9 kelch1repeat1and1BTB1domain1containing112 Other other
KDELC2 2.0 KDEL1motif1containing12 Other other
L1TD1 3.3 LINEF11type1transposase1domain1containing11 Other other
LAIR1 3.0 leukocyte1associated1immunoglobulin1like1receptor11 Plasma1Membrane transmembrane1receptor
LINC00294 2.2 long1intergenic1nonFprotein1coding1RNA1294 Other other
LINC00410 5.1 long1intergenic1nonFprotein1coding1RNA1410 Other other
C14orf23 2.6 long1intergenic1nonFprotein1coding1RNA11551 Other other
LOC100190986 4.0 uncharacterized1LOC100190986 Other other
LOC643406 2.4 uncharacterized1LOC643406 Other other
LYZ 2.6 lysozyme Extracellular1Space enzyme
MAB21L3 2.9 mabF211like13 Other other
MAP1LC3C 2.2 microtubule1associated1protein111light1chain131gamma Cytoplasm other
MAP7D3 2.3 MAP71domain1containing13 Cytoplasm other
MBOAT1 2.4 membrane1bound1OFacyltransferase1domain1containing11 Cytoplasm other
MEFV 3.1 Mediterranean1fever Nucleus other
MTFMT 2.1 mitochondrial1methionylFtRNA1formyltransferase Cytoplasm enzyme
LOC90834 3.9 NA NA NA
LOC731424 3.4 NA NA NA
LOC728558 3.0 NA NA NA
LOC147670 3.0 NA NA NA
LOC145663 2.5 NA NA NA
LOC100190938 2.5 NA NA NA
LOC642236 2.4 NA NA NA
NLRP12 2.9 NLR1family,1pyrin1domain1containing112 Cytoplasm other
NPIPL3 3.4 nuclear1pore1complex1interacting1protein1family1member1B3 Other other
NT5DC3 2.5 5'Fnucleotidase1domain1containing13 Other other
NUAK2 2.9 NUAK1family1kinase12 Other kinase
NXN 2.4 nucleoredoxin Nucleus enzyme
ORAI2 2.6 ORAI1calcium1releaseFactivated1calcium1modulator12 Plasma1Membrane other
OTUD6A 2.1 OTU1deubiquitinase16A Other peptidase
P2RX5FTAX1BP3 2.4 P2RX5FTAX1BP31readthrough1(NMD1candidate) Other other
PDDC1 2.1 Parkinson1disease171domain1containing11 Cytoplasm other
PDE6A 2.4 phosphodiesterase16A Plasma1Membrane enzyme
PGM2L1 2.0 phosphoglucomutase12Flike11 Cytoplasm enzyme
PGM5P2 2.1 phosphoglucomutase151pseudogene12 Other other
PPP1R3B 3.2 protein1phosphatase111regulatory1subunit13B Cytoplasm other
PRR11 2.2 proline1rich111 Other other
PSTPIP2 2.2 prolineFserineFthreonine1phosphatase1interacting1protein12 Cytoplasm other
RBMS2 2.2 RNA1binding1motif1single1stranded1interacting1protein12 Nucleus other
RPS6KA3 2.3 ribosomal1protein1S61kinase1A3 Cytoplasm kinase
RRP7B 3.0 ribosomal1RNA1processing171homolog1B,1pseudogene Other other
KIAA0226 2.0 RUN1and1cysteine1rich1domain1containing1beclin111interacting1protein Cytoplasm other
RUNDC1 2.2 RUN1domain1containing11 Other other
SCAI 2.3 suppressor1of1cancer1cell1invasion Nucleus transcription1regulator
SCD5 3.4 stearoylFCoA1desaturase15 Cytoplasm enzyme
SERPINB9 2.3 serpin1family1B1member19 Cytoplasm other
SGSM1 3.3 small1G1protein1signaling1modulator11 Nucleus other
SKA1 2.1 spindle1and1kinetochore1associated1complex1subunit11 Nucleus other
MCART1 2.3 solute1carrier1family1251member151 Cytoplasm other
SLC7A5P2 2.9 solute1carrier1family171member151pseudogene12 Other other
SPRED1 2.5 sprouty1related1EVH11domain1containing11 Plasma1Membrane other
STAC2 3.1 SH31and1cysteine1rich1domain12 Other other
FAM40B 2.4 striatin1interacting1protein12 Cytoplasm other
STYX 2.1 serine/threonine/tyrosine1interacting1protein Cytoplasm phosphatase
TACC2 3.2 transforming1acidic1coiledFcoil1containing1protein12 Nucleus other
TADA2B 2.5 transcriptional1adaptor12B Nucleus other
TAF8 2.0 TATAFbox1binding1protein1associated1factor18 Nucleus transcription1regulator
TBXA2R 2.6 thromboxane1A21receptor Plasma1Membrane GFprotein1coupled1receptor
TLCD2 2.6 TLC1domain1containing12 Other other
TNFAIP8L1 2.9 TNF1alpha1induced1protein181like11 Cytoplasm other
TSIX 2.6 TSIX1transcript,1XIST1antisense1RNA Nucleus other
UCKL1FAS1 3.2 UCKL11antisense1RNA11 Other other
UTP3 2.2 UTP3,1small1subunit1processome1component1homolog1(S.1cerevisiae) Nucleus other
VPS53 2.2 VPS53,1GARP1complex1subunit Cytoplasm other
VSIG1 3.2 VFset1and1immunoglobulin1domain1containing11 Plasma1Membrane other
VSTM4 3.3 VFset1and1transmembrane1domain1containing14 Other other
WDR45 2.2 WD1repeat1domain145 Other other
WNT7B 2.4 Wnt1family1member17B Extracellular1Space other
XIST 2.1 X1inactive1specific1transcript1(nonFprotein1coding) Nucleus other
ZC3H12D 3.1 zinc1finger1CCCHFtype1containing112D Cytoplasm other
ZFYVE19 2.6 zinc1finger1FYVEFtype1containing119 Cytoplasm other
ZKSCAN3 2.6 zinc1finger1with1KRAB1and1SCAN1domains13 Nucleus transcription1regulator
ZMAT3 2.3 zinc1finger1matrinFtype13 Nucleus other
ZNF124 2.3 zinc1finger1protein1124 Nucleus other
ZNF264 2.6 zinc1finger1protein1264 Nucleus other
ZNF347 2.5 zinc1finger1protein1347 Nucleus other
ZNF490 2.5 zinc1finger1protein1490 Nucleus other
ZNF526 2.2 zinc1finger1protein1526 Other other
ZNF793 2.6 zinc1finger1protein1793 Other other
ZNF805 2.8 zinc1finger1protein1805 Other other
ZNF814 2.7 zinc1finger1protein1814 Other other
ZSCAN22 2.7 zinc1finger1and1SCAN1domain1containing122 Nucleus transcription1regulator
ST1.1$=$Genes$Upregulated$in$SK=BR=3$Nuclei$Compared$to$Cells
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 We next investigated whether any biological differences could be detected between nuclear 
and cellular transcriptomes.  Our data suggest that the overall expression level and abundance of 
genes are very similar (rs = 0.95) between nuclei and whole cells, consistent with the bulk experiments 
(Figure 10a).  Analysis of gene expression variance showed a bell-shaped curve, high correlation 
(rho=0.451, Spearman Correlation) of gene expression values between all cells, and gene dropouts at  
Table 2 - Significant differentially expressed genes between SK-BR-3 whole cells and nuclei. ST1.1 
lists all of the genes upregulated in nuclei compared to cells.  ST1.2 lists all of the genes 
downregulated in nuclei compared to cells.  Columns listed include Gene Identifier (Gene ID), Fold-
change, Entrez Gene Name, cellular localization and gene class. 
Gene$ID FoldChange Entrez$Gene$Name cellular$localization gene$class
PTS $2.3 6$pyruvoyltetrahydropterin7synthase Cytoplasm enzyme
AP2S1 $2.2 adaptor7related7protein7complex727sigma717subunit Cytoplasm transporter
ARF4 $2.1 ADP7ribosylation7factor74 Cytoplasm enzyme
ALG14 $2.5 ALG14,7UDP$N$acetylglucosaminyltransferase7subunit Cytoplasm enzyme
ASNS $2.2 asparagine7synthetase7(glutamine$hydrolyzing) Cytoplasm enzyme
BOLA3 $2.6 bolA7family7member73 Other other
CD9 $2.3 CD97molecule Plasma7Membrane other
CKS1B $2.4 CDC287protein7kinase7regulatory7subunit71B Other kinase
CETN2 $2.1 centrin72 Nucleus enzyme
C11orf73 $2.0 chromosome7117open7reading7frame773 Cytoplasm transporter
COMMD3 $2.3 COMM7domain7containing73 Other other
COPS4 $2.0 COP97signalosome7subunit74 Cytoplasm other
CNIH $2.3 cornichon7family7AMPA7receptor7auxiliary7protein71 Plasma7Membrane other
C7orf44 $2.5 cytochrome7c7oxidase7assembly7factor717homolog Cytoplasm other
DAZAP2 $2.0 DAZ7associated7protein72 Nucleus other
DRAM2 $2.5 DNA7damage7regulated7autophagy7modulator72 Cytoplasm other
ESD $2.3 esterase7D Cytoplasm enzyme
EIF5A $2.0 eukaryotic7translation7initiation7factor75A Cytoplasm translation7regulator
FOS $2.1 FBJ7murine7osteosarcoma7viral7oncogene7homolog Nucleus transcription7regulator
GABARAPL2 $2.5 GABA7type7A7receptor7associated7protein7like72 Cytoplasm other
GTF2IP1 $5.3 general7transcription7factor7IIi7pseudogene71 Other other
GNPDA1 $2.2 glucosamine$6$phosphate7deaminase71 Cytoplasm enzyme
GSTM4 $2.0 glutathione7S$transferase7mu74 Cytoplasm enzyme
CGA $2.1 glycoprotein7hormones,7alpha7polypeptide Extracellular7Space other
H3F3AP4 $2.7 H37histone,7family73A,7pseudogene74 Other other
HIGD1A $2.1 HIG17hypoxia7inducible7domain7family7member71A Cytoplasm other
HAT1 $2.1 histone7acetyltransferase71 Nucleus enzyme
IGFL1 $3.6 IGF7like7family7member71 Extracellular7Space other
ID1 $3.1 inhibitor7of7DNA7binding71,7HLH7protein Nucleus transcription7regulator
ID3 $2.0 inhibitor7of7DNA7binding73,7HLH7protein Nucleus transcription7regulator
ITGB3BP $2.2 integrin7subunit7beta737binding7protein Nucleus other
JKAMP $2.9 JNK1/MAPK8$associated7membrane7protein Cytoplasm other
LAMTOR1 $2.0 late7endosomal/lysosomal7adaptor,7MAPK7and7MTOR7activator71Plasma7Membrane other
MAD2L1 $2.1 MAD27mitotic7arrest7deficient$like717(yeast) Nucleus other
MEMO1 $2.3 mediator7of7cell7motility71 Cytoplasm other
MT1X $2.2 metallothionein71X Other other
MGST1 $2.0 microsomal7glutathione7S$transferase71 Cytoplasm enzyme
BRP44 $2.6 mitochondrial7pyruvate7carrier72 Plasma7Membrane other
MRPL39 $2.1 mitochondrial7ribosomal7protein7L39 Cytoplasm other
MRPS14 $2.2 mitochondrial7ribosomal7protein7S14 Cytoplasm other
MRPS23 $2.1 mitochondrial7ribosomal7protein7S23 Cytoplasm other
LOC440354 $2.1 NA NA NA
LOC541471 $2.1 NA NA NA
LOC550643 $2.0 NA NA NA
NDUFAF4 $2.2 NADH:ubiquinone7oxidoreductase7complex7assembly7factor74Cytoplasm other
NIT2 $2.2 nitrilase7family7member72 Cytoplasm enzyme
NUTF2 $2.0 nuclear7transport7factor72 Nucleus transporter
C20orf111 $2.2 oxidative7stress7responsive7serine7rich71 Other enzyme
PDZD11 $2.5 PDZ7domain7containing711 Extracellular7Space other
PRDX3 $2.3 peroxiredoxin73 Cytoplasm enzyme
PIGU $2.3 phosphatidylinositol7glycan7anchor7biosynthesis7class7U Cytoplasm enzyme
PHLDA2 $2.9 pleckstrin7homology7like7domain7family7A7member72 Cytoplasm other
POLR2G $2.0 polymerase7(RNA)7II7subunit7G Nucleus enzyme
POLR2K $2.5 polymerase7(RNA)7II7subunit7K Nucleus enzyme
PFDN1 $2.2 prefoldin7subunit71 Cytoplasm transcription7regulator
PPP6C $2.0 protein7phosphatase767catalytic7subunit Nucleus phosphatase
PLP2 $2.5 proteolipid7protein727(colonic7epithelium$enriched) Cytoplasm transporter
RPA3 $2.0 replication7protein7A3 Nucleus other
RPL21 $2.7 ribosomal7protein7L21 Cytoplasm other
SAMM50 $2.2 SAMM507sorting7and7assembly7machinery7component Cytoplasm other
C19orf42 $2.2 small7integral7membrane7protein77 Other other
TAX1BP3 $2.6 Tax17binding7protein73 Cytoplasm transcription7regulator
TXNDC12 $2.3 thioredoxin7domain7containing712 Cytoplasm enzyme
TMX2 $2.2 thioredoxin7related7transmembrane7protein72 Other enzyme
TMEM106C $2.5 transmembrane7protein7106C Other other
TMEM14A $3.6 transmembrane7protein714A Other other
TMEM18 $2.3 transmembrane7protein718 Nucleus other
TMEM99 $2.6 transmembrane7protein799 Other other
TSFM $2.5 Ts7translation7elongation7factor,7mitochondrial Cytoplasm translation7regulator
UBE2T $2.0 ubiquitin7conjugating7enzyme7E27T Nucleus enzyme
VPS25 $2.6 vacuolar7protein7sorting7257homolog Cytoplasm other
VDAC3 $2.0 voltage7dependent7anion7channel73 Cytoplasm ion7channel
WDR83OS $2.1 WD7repeat7domain7837opposite7strand Other other
WDYHV1 $2.5 WDYHV7motif7containing71 Cytoplasm other
ZNF706 $2.0 zinc7finger7protein7706 Other other
ST1.2$>$Genes$Downregulated$in$SK>BR>3$Nuclei$Compared$to$Cells
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lower expression levels, justifying for the use of the zero-inflated negative binomial SCDE statistical 
model (Figure 11).  In total we detected only 6.66% (196/2942) genes that were significantly  
 
differentially expressed using SCDE(158) (FDR adjusted p-values < 0.05 and |log2(fold change)| >= 
1).  Gene ontology and pathway analysis of these genes showed higher levels of LINC RNAs, 
pseudogenes and nuclear-function genes in the nucleus compared to cells, while conversely the nuclei 
showed low levels of mitochondrial and transmembrane genes, which were higher levels in the cells 
(Figure 10b, Table 2).  We also investigated whether the known RNA or protein localization in 
cellular compartment showed any correlation with whether the RNA was expressed at high levels in 
the nuclei or cells (Figure 10c).  These data show that proteins and RNA that localize to the nucleus 
are significantly elevated in nuclei, whereas proteins and RNA that localize to the cytoplasm are 
higher in cells. 
 We further investigated whether any cancer genes or pathways were differentially expressed 
in the nuclei and whole cells.  We performed GSVA analysis(164) using 189 oncogenic gene set  
Supplementary Table 2 - Differentially Enriched Oncogenic Gene 
Signatures Between SK-BR-3 Single Nuclei and Cells
GeneSet Identifier Avg_diff pval adjPval
CSR LATE UP.V1 UP 0.118060921 7.22E-38 1.14E-36
EIF4E UP 0.11607917 3.70E-56 2.33E-54
RB DN.V1 UP 0.102414964 1.19E-40 2.49E-39
GeneSet Identifier Avg_diff pval adjPval
HINATA NFKB IMMU INF -0.10104583 1.38E-13 5.23E-13
CSR EARLY UP.V1 DN -0.11034172 2.12E-73 4.01E-71
Whole Cell Enriched oncogenic genesets
Nuclei Enriched oncogenic genesets
Table 3 - The 5 out of 189 significant differentially enriched oncogenic gene signatures identified by 
GSVA analysis between single nuclei and single cells.  Columns listed include the Gene Signature 
Identifier, Average difference of GSVA score between nuclei and whole cells (Avg_diff), p-value 
(pval) and FDR adjusted p-value (adjPval). 
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Figure 10 – Concordance in gene expression between single whole cells and nuclei.  (a) Scatter plot 
of average gene expression [log2(count+1)] of 485 single nuclei and 424 single cells, with 196 
significantly differential genes labeled in purple and Spearmans’s correlation values indicated.  (b) 
Heatmap of selected differentially expressed genes that are LINC RNAs, pseudogenes, nuclear-
function genes, mitochondria or transmembrane. (c) Protein and RNA localization enrichment 
analysis comparing genes overexpressed in the nucleus or cells. (d) Venn diagram and volcano plot of 
GSVA scores for 189 oncogenic gene sets expressed in nuclei or cells. (e) Boxplots for 40 TCGA 
breast cancer genes grouped by nuclei or cells, with a star indicating significant differential expression 
in the CKS1B gene. (f) Breast cancer subtypes of single cells or nuclei predicted with the PAM50 
gene signature. The frequency concordance was determined as non-significant by the Wilcoxon 
matched-pairs signed rank test, where p-value > 0.4. (g) Clustered heatmap of single cell or nuclei 
copy number profiles calculated from RNA data, compared to whole-genome-sequencing data 
labeled as pop.  Breast cancer genes are annotated on the WGS track. 
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signatures (MSiDB v5.2)(165), which showed that most signatures (97.35%) were highly concordant, 
but that 5/189 gene sets were differentially expressed (Figure 10d, Table 3). The differentially 
expressed gene signatures include 3 pathways that were upregulated in the nucleus (EIF4E 
translation and nuclear export factors, RB cell cycle signaling and CSR serum starvation response) 
and 2 pathways that were upregulated in the whole cells (NFKB inflammation and CSR serum 
	f 
g 
 53 
starvation response).  We also examined the expression levels of 40 breast cancer genes that are 
frequently deregulated in TCGA(13) (Figure 10e).  Only one gene, CDC28 protein kinase regulatory 
subunit 1B (CKS1B), was found to be significantly lower (2.4-fold) in the nuclei compared to the 
cells. We also applied the PAM50 gene signature(193) to classify single cells into the 5 major clinical 
breast cancer expression subtypes (Normal-like, Luminal A, Luminal B, Her2 or Basal-like). The 
relative frequency shifted slightly in each group, however it was not significant by concordance test 
(p-value > 0.4).  These data showed that most of the single cells and nuclei were classified as Her2 
Figure 11 - Calculation of data variation between gene expression levels in single whole cell and 
single nuclei data from SK-BR-3. (a) Variance of all detectable genes in SK-BR-3 single cell data as a 
function of mean expression levels. (b) Pair-wise correlation heatmap of all single nuclei and single 
cells using 4414 top detected genes. (c) Scatter plot of two representative single cell gene expression 
levels in log2(count+1) scale. (d) Scatter plot of single cell and single nuclei within group variations 
of 196 significant genes detected between both groups by SCDE. 
a b 
c d 
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positive, consistent with the report that SK-BR-3 is a Her2 positive cell line by 
immunohistochemistry(194).  However, we also found that a subset of the single cells were classified 
as luminal B (10.7, 23.6%), basal-like (1.8, 5.9%), normal-like (0.4, 1.4%) or luminal A (2.4, 3.3%) in 
both the nuclei and cells (frequency concordance P > 0.4), suggesting that the population of cells 
represented a composite mixture of molecular subtypes (Figure 10f).  
We used the single cell gene expression data to calculate genomic copy number profiles at 
~1 megabase resolution.  A similar approach was previously applied to single cell RNAseq data from 
glioblastoma patients(47).  In our data we found that the copy number profiles of nuclei and whole-
cells were highly concordant (Pearson’s r =0.91) and identified several large-scale amplifications, 
including 1q (MDM4), 7p, 8q (MYC), 17q (HER2), 19 and 20 (BCAS1) and deletions of 6q, 11p, 13, 
17p (TP53), 18 (DCC) and Xp (Figure 10g).  However, neither the single cell nor nuclei copy number 
profiles could accurately resolve the smaller (<10mb) chromosome deletions and amplifications, and 
we did not detect the MET amplification on chromosome 7q.  The correlation between the single 
cell or nuclei profiles and the whole-genome sequencing results was r =0.38 (Pearson Correlation).  
Collectively these data suggest that transcriptome profiles of nuclei are highly representative of 
whole-cells, and can be used to study many cancer genes and signaling pathways. 
 
3.2.4 Phenotypic Diversity of Single Nuclei from a Breast Tumor 
We applied nanogrid SNRS to study tumor subpopulations and transcriptional diversity in a triple-
negative (ER-, PR- and HER2-) breast tumor that was cryopreserved for 2 years.  Nuclear 
suspensions were generated from the frozen tumor and 502 nuclei were sequenced using cDNA  
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obtained with the nanogrid platform.  In total we identified 1421 wells with single nuclei during the 
imaging step and selected 502 wells with larger nuclei (>8 microns) to increase the tumor purity and 
avoid sequencing normal stromal cells.  The tumor purity was estimated by histopathology to be 
41%.  The data metrics resulted in an average of 975,097 reads, 14,886 UMI counts and 3,619 genes 
per nucleus (Figure 12).  We also used nanogrid SNRS to sequence 380 nuclei from a normal breast 
tissue sample.  To distinguish between tumor and stromal cells, we calculated the genomic copy 
number profile of each nucleus and clustered the data together with the normal breast tissue nuclei 
Figure 12 - Sequence data metrics calculated for single nuclei from the triple-negative breast tumor 
analyzed by nanogrid SNRS, including: (a) Sequence read mapping rates to the human genome 
reference assembly, (b) number of mapped reads per nucleus, (c) number of mapped reads in 
millions, (d) number of unique molecular identifiers detected in single nuclei, (e) read tags mapped to 
coding regions, (f) read tags mapped to intronic regions, (g) number of mapped reads per cell as a 
function of gene coverage, (h) ribosomal RNA mapped reads, (i) mapped reads to the 3’ untranslated 
region. 
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that showed diploid copy number profiles (Figure 13a).  In our previous work, we have shown that 
most tumor cells in breast cancer are aneuploid, while most normal cells have diploid profiles with 
no evidence of somatic mutations(12, 17).  Hierarchical clustering of the copy number data identified 
5/502 cells with normal diploid copy number profiles representing stromal cells (Figure 13a, green 
arrows) and 497 cells with aneuploid tumor profiles.  The aneuploid tumor cells had amplifications in 
chromosomes 1q (MDM4), 19q (AKT2) and deletions on chromosome 1p, 3, 4, 11p, 12q (MDM2), 
17p (TP53), 19q, 22.  These data suggest that the purity of the tumor cells increased from 41% to 
99% using the automated imaging and selection of nanogrid wells with larger nuclei (Figure 13b).  
We identified 497 tumor cells that had aneuploid copy number profiles and 5 normal breast tissue 
cells with diploid copy number profiles from this analysis. 
 We first applied MAST(160, 161) to identify differentially expressed cancer genes (FDR 
adjusted p-value<0.05 and [log2 (fold change)] ≥1 ) between single tumor cells (N=497), stromal cells 
(N=5) and normal breast cells (N=240).  This identified 30/229 known cancer genes (T200 targeted 
platform) and 11/40 TCGA breast cancer genes that were differentially expressed relative to the 
normal breast cells, including KRAS, GATA3, CCND1, CDH1, GNAS.  Most of these genes were 
expressed across all tumor cells; however, a few cancer genes, including AURKA and TOP2A were 
restricted to a minor subpopulation. 
To further understand phenotypic variability within the tumor cells, we focused on the 497 
aneuploid tumor cells and performed PCA linear dimension reduction to identify the top variable 
genes from the first 5 principal components (49.34% variance explained) for unsupervised clustering 
using shared nearest neighbor (SNN) modularity optimization(171) (Figure 13c) and tSNE(174), 
which was implemented with the SEURAT package(112)(Figure 5c-e).  This analysis identified 3 
subpopulations of tumor cells (clusters A, B, C).  Subpopulation A consisted of 217 nuclei (52.2%) 
and showed overexpression of 7 genes compared to other tumor subpopulations, which did not 
include any known cancer genes.  Subpopulation B consisted of 121 cells (29.1%) and showed 
overexpression of 13 genes, including 7 cancer genes (HSPB1, ANXA1, SLPI, KRT8, KRT19, KLK7  
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Figure 13 –	Gene expression analyses of single breast tumor nuclei.  ( a) Clustered heatmap of single 
nuclei RNA copy number profiles isolated from tumor tissue or normal breast tissue.  Green arrows 
indicate 5 stromal cells from the tumor with diploid copy number profiles. Bar-plot shows increase in 
tumor purity after image-selection of larger nuclei. (b) Enrichment of tumor cells using nanogrid 
SNRS from 41% to 99%.  (c) t-SNE projection of single nuclei in high-dimensional space with SNN 
clustering of three subpopulations (A, B, C) indicated by color. (d) Clustered heatmap of single nuclei 
RNA expression profiles using differentially expressed genes.  Cancer genes are highlighted in red 
and the three major clusters are indicated by color. (e) t-SNE plots of single cells showing gene 
expression levels of individual genes. (f) GSVA scores for a subset of oncogenic phenotypes with 
single nuclei sorted by each row independently with header bars indicating their identities of the 
predicted subpopulations. (g) Clustered heatmap of cell cycle signature scores for single nuclei with 
subpopulation indicated in the header. (h) Subtype signature classifications for single tumor nuclei 
predicted by PAM50 for the 5 breast cancer subtypes (left) and for the 6 TNBC subtypes (right).   
a 
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and ABL2) and several Keratin genes (KRT8, KRT7, KRT19, KRT6B). Subpopulation C was the 
rarest subpopulation (18.8%), consisting of 78 cells, but had the highest number of cancer genes 
(N=13) that were overexpressed (MKI67, TOP2A, PRC1, CDK1, AURKA, CKS2, BIRC5, DEPDC1, 
UBE2C, NEK2, BRCA2 and ECT2). Several genes that were differentially expressed in 
subpopulation C are involved in DNA damage repair (BRCA2, RAD51AP1, HMGB2), apoptosis 
(BIRC5, DEPDC1) and mitosis or cell cycle regulation, including high expression of Ki-67 (MKI67), 
a marker of cell proliferation.  To determine if the expression of the 13 cancer genes was truly 
restricted to the minor C subpopulation, we plotted the individual gene expression levels of single 
cells using Violin plots (Figure 13e).  These data confirmed that most of the cancer genes were highly 
elevated in subpopulation C and had low expression in the A and B subpopulations.   
Due to the high level of Ki-67 in subpopulation C, we performed gene signature analyses for 
the cell cycle stages (G1, S, M, G2) in all of the tumor nuclei (Figure 13g).  These data showed that 
many of the subpopulation C tumor cells were in the G2 or M-phase of the cell cycle, suggesting an 
actively proliferating subpopulation, while many cells from subpopulation A and B were in the G1 
phase or G0 (absence of scores). Our data suggest that while subpopulation C was the minor 
subpopulation in the tumor mass, it also had the most malignant cancer phenotypes.  The nuclei in 
subpopulation C are likely to be in the G2 or M-phase, because the nuclear membrane does not 
break down until prometaphase of mitosis and is re-formed during telophase.  Therefore, there are 
still some nuclei in prophase, prometaphase, telophase, and cytokinesis, that are mitotic. Interestingly, 
the imaging data of nuclear signal and size showed that cells in the G2 or M-phase had significantly 
larger sizes compared to those in other stages of the cell cycle (Figure 14), which is consistent with 
previous observations that G2/M cells have larger nuclear diameters(195, 196).  Our analysis of the 
cell cycle data estimate that 18.75% of the cells were in the G2/M stage of the cell cycle, suggesting 
that we did not bias strongly against other cell cycle stages by the selection of larger nuclei during the 
nanowell imaging steps.  
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 We further investigated the diversity of the classical breast cancer subtypes and oncogenic 
gene signatures at single cell resolution.  GSVA analysis identified variation in the gene signatures for 
a number of cancer phenotypes, including stemness, proliferation, and angiogenesis (Figure 13f).  
Consistent with our previous analysis, we found that subpopulation C was enriched for cell 
proliferation, while subpopulation A showed low scores for proliferation.  The GSVA data further 
showed that subpopulation B had higher scores for hypoxia, invasiveness, migration, apoptosis and  
glycolosis.  Next, we used the PAM50 gene signature(193) to investigate the diversity of the 5 major 
breast cancer subtypes and found that most cells were of the basal-like (156/416) subtype, which is 
expected since this subtype is commonly associated with TNBC patients(193).  However, we also 
identified a significant fraction of single tumor nuclei that were Her2 positive (15.6%), luminal A 
(3.4%), luminal B (26.4%) and normal like (17.1%), suggesting that the tumor was a mixture of 
different subtypes (Figure 13h).  Studies have also shown that TNBC patients can be further 
classified into 6 additional subtypes based on gene expression signatures:  mesenchymal (M), 
mesenchymal stem-like (MSL), luminal androgen receptor (LAR), immunomodulatory (IM), basal-
like 1 (BL1) and basal-like 2 (BL2)(194).  We applied the TNBC subtype signature to the basal-like 
tumor nuclei and showed that most nuclei were classified as mesenchymal stem-like (90.1%) but that 
Figure 14 - Boxplots of DAPI-staining intensities of G2/M single nuclei and G1/0/S single nuclei 
as inferred by RNA-seq data was matched to automated imaging data from the nanogrid system, 
showing larger nuclear sizes in the G2/M cells. 
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a few cells were immunomodulatory (4%) or belonged to the other TNBC subclasses (Figure 13h).  
These data suggest that tumor nuclei demonstrate diverse cancer phenotypes and subtype 
classifications within a single patient tumor. 
 
3.3 Discuss ion  
In this study we report a novel nanogrid SNRS technology that performs high-throughput single 
nuclei imaging, selection and sequencing in an integrated platform. Nanogrid sequencing has several 
technical advantages over existing high-throughput single cell RNA sequencing methods that use 
microwells(108, 183, 184) or microdroplet encapsulation(110, 112).  Our system enables automated 
imaging of the 5184 wells that contain single cells or nuclei with fluorescent channels, followed by 
selection of specific nanowells for nanodepositing of WTA reagents. Imaging and selection of single 
cells is not technically feasible using microdroplet or microwell methods(110, 112).  With nanogrid 
imaging, we can reduce cell doublets and exclude dead cells by imaging.  Another technical study 
using the nanowell platform estimated the doublet error rate to be 2.4% by human-mouse mixing 
experiments(153).  Additionally, by staining nuclei with DAPI, our approach can select larger nuclei, 
and thereby increase the purity of the tumor cells to 99%.  This addresses a major issue in standard 
RNAseq studies of tumor tissues wherein many normal stromal cells often affect gene signature 
analyses.   While a previous study has combined robotic micromanipulation and imaging(197) to 
perform low-throughput single cell RNA sequencing (about 10 minutes per cell) and individual single 
cell library construction, the nanogrid system completes imaging of all 5184 wells in only 10 minutes 
and requires only a single sequencing library to be constructed for sequencing analysis.  This greatly 
reduces the cost to about $2.20 per cell, with the cost per 1800-cell library at $1.10 per cell and the 
sequencing cost of $1.10 per cell for achieving 220K reads/cell on a HiSeq4000 system (Illumina).  
Another study developed a nanowell system that uses barcoded mRNA capture beads to create a 
portable, low-cost system called Seq-Well(198).  While very cost effective and high-throughput, this 
system did not allow selection of imaged nanowells, which is an advantage of our platform. 
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 We applied the nanogrid SNRS to study the transcriptional differences of cells and nuclei in 
a breast cancer cell line, showing a high concordance in transcript abundance and expression levels. 
These data challenge the long-standing paradigm that nuclear transcriptomes are not representative 
of whole cells. However, our data are consistent with recent studies in neural cell types that have 
reported a high concordance between the transcriptional profiles of nuclei and whole cells(109, 186-
188). We further applied nanogrid SNRS to study a frozen tumor sample from a TNBC patient that 
was cryopreserved for about 2 years. On a parenthetical note, we do not expect that length of 
freezing will have a major effect on the stability of nuclear RNA, although multiple freeze-thaw 
cycles may lead to RNA degradation.  In the TNBC tumor data, we identified a minor (19%) 
subpopulation of tumor cells that were highly proliferative and overexpressed many cancer genes. 
Our data also showed phenotypic heterogeneity in stemness, angiogenesis and proliferation, as well 
as the co-existence of multiple breast cancer subtypes in single cells from an individual tumor.  These 
data are consistent with a recent single cell RNA sequencing study in glioblastoma that showed 
variation in EMT and the co-existence of many clinical subtypes within an individual patient tumor.  
The striking amount of pre-existing phenotypic variation may explain why TNBC patients evolve 
rapid resistance to neoadjuvant chemotherapy(199-201).  
 Although the majority of nuclear and cytoplasmic genes were concordant, we did identify a 
few differences in LincRNAs, pseudogenes, mitochondrial genes and nuclear-function genes.  These 
data are consistent with previous work showing that pseudogenes and LincRNAs are transcribed and 
preferentially located in the nucleus over the cytoplasm(202, 203).  Our data also determine that 
mitochondrial genes are not expressed at high levels in the nucleus, which is consistent with the 
localization of the mitochondria in the cytoplasm(204). We also found an increased abundance of 
intronic sequences in the nucleus, which is expected based on our knowledge of alternative splicing 
of pre-mRNA in the nucleus(191, 192).  Importantly, our data indicate that these gene expression 
differences did not have a major influence on the measurement of most cancer genes and signaling 
pathways.  
 64 
In closing, the SNRS nanogrid system opens up new avenues of investigation into the 
analysis of single nuclei transcriptomes from frozen tissue sections.  In addition to imaging live and 
dead cells and applying the parameter nuclear size, the nanogrid imaging approach is flexible and can 
be applied broadly to identify cell types of interest based on fluorescent markers.  We expect that the 
SNRS nanogrid approach will benefit not only cancer research, as demonstrated in this study, but will 
also benefit many diverse fields of biomedical research, where the analysis of single nuclei from 
frozen tissue samples can provide new insights into human diseases. 
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CHAPTER 4: CHEMORESISTANCE EVOLUTION IN TRIPLE-NEGATIVE BREAST 
CANCER DELINEATED BY SINGLE CELL SEQUENCING 
 
[Note: This chapter is based on a manuscript that has been accepted by Cell (Kim and Gao et al. 
2018).]  
 
4 .1 Introduc t ion  
Triple-negative breast cancer (TNBC) is an aggressive subtype that constitutes 12-18% of breast 
cancer patients (2).  TNBC patients lack the estrogen receptor (ER), progesterone receptor (PR) and 
HER2 receptor and therefore are not eligible for hormone or anti-Her2 therapy.  Deep-sequencing 
studies (11, 15, 205), multi-region sequencing analysis (28), and single cell sequencing studies (12, 16, 
17) have shown that TNBC patients harbor high levels of somatic mutations, frequent mutations in 
TP53 (83%) and complex aneuploid rearrangements (80%) that result in extensive intratumor 
heterogeneity (ITH).  
The standard of care for many TNBC patients is neoadjuvant chemotherapy (NAC), which 
includes a combination of taxanes (mitotic inhibitors) and anthracyclines (DNA intercalators).  While 
NAC is effective in some TNBC patients, about 50% evolve resistance, leading to poor overall 
survival (2, 7).  The genomic and molecular basis of chemoresistance in TNBC patients remains 
poorly understood, in part due to a lack of methods that can resolve ITH and detect genomic 
information in rare subpopulations.  A major gap in knowledge is whether chemoresistance arises 
due to the selection and expansion of rare pre-existing subclones (adaptive resistance), or, 
alternatively, through the induction of new mutations that confer a chemoresistant phenotype 
(acquired resistance) (54).  This question has been studied for decades in bacterial systems, since the 
seminal fluctuation experiments by Luria & Delbruck (55) but remains poorly understood in most 
human cancers. 
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Genomic studies of therapy resistance have reported both acquired resistance (24, 63, 128, 
206) and adaptive resistance (24, 64) to systemic chemotherapies.  In acute myeloid leukemia, whole-
genome sequencing before and after chemotherapy identified different modes of clonal evolution, 
with some patients acquiring relapse-specific mutations, while others selecting minor clones (24).  In 
high-grade serous ovarian cancer, platinum-based chemotherapy was shown to induce new somatic 
mutations consistent with acquired resistance (63), while resistance to cytotoxic chemotherapy in 
bladder cancer was associated with the selection of pre-existing subpopulations (64).  In 
glioblastoma, treatment with temozolomide induced many new mutations in post-treatment tumor 
samples consistent with an acquired model of therapy resistance (128, 206). 
Previous work on chemoresistance in TNBC patients has mainly used in situ hybridization 
methods (65) and bulk genomic profiling techniques (15, 205).  With targeted cytogenetic markers, 
one study showed that genetic diversity did not change in response to NAC but instead selected for 
mesenchymal phenotypes (65). Another study in TNBC used next-generation sequencing (NGS) to 
profile residual disease in post-treatment chemotherapy samples and identified a number of clinically 
actionable mutations (15).  In another report, authors identified JAK2 amplifications as a potential 
therapeutic target to overcome resistant disease (66).  However these studies were based on targeted 
markers or bulk genomic tissue profiling and had limited ability to reconstruct clonal evolution 
during chemotherapy. 
Single cell DNA (12, 17) and RNA (42, 43, 108, 207) sequencing methods have emerged as 
powerful tools for fully resolving ITH, reconstructing evolutionary lineages, and detecting rare 
subpopulations (109, 208).  The application of single cell DNA and RNA sequencing methods to 
solid tumors has enabled phylogenetic reconstruction of tumor lineages (11, 12, 17), resolved rare 
subpopulations (106, 197) and have provided insight into the phenotypes of stromal and tumor cells 
in different cancer types (47, 127, 209). We reasoned that these technologies could overcome many 
of the technical hurdles that have previously challenged genomic studies of chemoresistance in 
TNBC patients.   
 67 
Due to the extensive ITH reported in TNBC patients, we hypothesized that genomic 
aberrations associated with chemoresistance are pre-existing in the tumor mass and adaptively 
selected in response to chemotherapy.  In this study we analyzed longitudinal frozen treatment  
samples collected from TNBC patients during NAC treatment.  We identified two classes of clonal 
dynamics in response to NAC, in which the mutations, CNAs and expression profiles were 
eliminated from the tumor, or persisted after NAC. In the clonal persistence patients, our data 
further showed that genomic mutations and copy number aberrations were adaptively selected in 
Figure 15 – Chemoresistance sample acquisition and study outline.  (a) Timeline of chemotherapy 
treatment schedule and sample acquisition.  A pre-treatment core biopsy was obtained prior to NAC, 
a mid-treatment core biopsy was attained after two cycles of NAC (docetaxel and epirubicin), and the 
surgical sample was obtained after four additional cycles of NAC in combination with bevacizumab.  
(b) For each longitudinal time-point sample, three analyses were performed, including bulk exome 
sequencing, single-cell copy number profiling and 3’ single-nucleus RNA sequencing using a 
nanogrid platform.  
 
a 
 
 
 
 
b 
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response to chemotherapy, followed by transcriptional reprogramming to evolve the resistant tumor 
mass.  Our approach of applying single cell DNA and single cell RNA sequencing allowed us to 
identify these unique genomic and phenotypic methods of chemoresistance evolution, which we 
would not have detected had we not used both methods.   
 
4.2 Resu l t s  
 
4.2.1 TNBC Patients Treated With Neoadjuvant Chemotherapy  
We focused our study on 20 treatment-naive TNBC patients with local disease who were treated with 
NAC (Table 4, Methods Section 2.1.1).  All patients were classified as TNBC based on the absence 
of estrogen receptor staining, progesterone receptor staining and HER2 copy number by FISH.  
NAC treatment included an anthracycline (epirubicin) and a taxane (docetaxel) for 2 cycles, after 
which patients received 4 cycles of the same chemotherapy in combination with an angiogenesis 
inhibitor (bevacizumab) (Figure 15a). Frozen core biopsy samples were collected pre-treatment, after 
2 cycles of therapy and during the surgical excision that occurred after 6 cycles of NAC.  To mitigate 
Patient Identifier Histological Type
Estrogen 
Receptor 
Baseline (IHC)
Progesterone 
Receptor 
Baseline (IHC)
Her2+ 
Baseline 
IHC
Her2+ FISH 
Confirmation
KI67/MIB1 
Proliferation
Stage (ypTNM); 
After Surgery
Tumor Grade: 
Baseline
P1 KTN126 IDC <10% <10% 0 or 1+ 40 ypT1/Tis N0 Not done
P2 KTN129 IDC <10% <10% 0 or 1+ 90 ypT1 N0 3
P3 KTN612 Other <10% <10% 0 or 1+ 35 ypTX/Tis N1 Not done
P4 KTN304 IDC <10% <10% 0 or 1+ 25 ypT0 N3 3
P5 KTN147 IDC <10% <10% 0 or 1+ 60 ypT0 N0 2
P6 KTN206 IDC <10% <10% 0 or 1+ 60 ypT1 N1 Not done
P7 KTN317 IDC <10% <10% 0 or 1+ 40 ypT0 N0 3
P8 KTN210 IDC <10% <10% 0 or 1+ 10 ypT1 N0 2
P9 KTN302 IDC <10% <10% 0 or 1+ 40 ypT1 N0 2
P10 KTN102 IDC <10% <10% 0 or 1+ 30 ypT3/Tis N3 3
P11 KTN132 IDC <10% <10% 2+ 5-6 copies 10 ypT0/Tis N0 3
P12 KTN134 IDC <10% <10% 0 or 1+ 30 ypT0 N0 3
P13 KTN215 Not done <10% <10% 2+ FISH not amplified 45 ypT0 N0 Not done
P14 KTN152 IDC <10% <10% 2+ FISH not amplified 90 ypT2 N2 3
P15 KTN615 Other <10% <10% 0 or 1+ 31 ypT1/Tis N0 Not done
P16 KTN316 IDC <10% <10% 0 or 1+ 40 ypT2/Tis N0 Not done
P17 KTN310 IDC <10% <10% 0 or 1+ 50 ypTX N1 3
P18 KTN115 IDC <10% <10% 0 or 1+ 50 ypT1 N0 2
P19 KTN501 IDC <10% <10% 0 or 1+ FISH not amplified N/A ypT1 N0 3
P20 KTN155 IDC <10% <10% 0 or 1+ 50 ypT1 N1 3
Table 4 - Histopathological and clinical data on the 20 triple-negative breast cancer patients that 
were analyzed in this study.  Columns in this table include: 1) patient number, 2) patient identifier in 
clinical trial, 3) histological type, where IDC = invasive ductal carcinoma, 4) estrogen receptor staining in 
percentage of cells measured by immunohistochemistry, 5) progesterone receptor staining in percentage of 
cells measured by immunohistochemistry, 6) HER2 receptor staining by immunohistochemistry, 7) 
HER2 receptor amplification as measured by FISH, 8) tumor proliferation, as measured by Ki-67 and MIB1 
expression, 9) TNM tumor stage after surgery, (yp = post-surgery; T = staging for main tumor; N = 
staging for lymph nodes; M = staging for non-lymph node metastases) and 10) tumor grade. 
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spatial variation from tumor sampling, two core biopsy samples from each time-point were collected, 
and large tissue sections from the post-treatment surgical samples were used for genomic analyses.  
Exome sequencing was performed on matchedlongitudinal samples from 20 TNBC patients, while 
focused single cell DNA and RNA sequencing were performed on a subset of 8 patients (Figure 
15b).  	
 
4.2.2 Clonal Extinction and Persistence of Mutations in Response to NAC  
To investigate mutational evolution in bulk tissue samples, we performed exome sequencing (mean  
depth 173×) on matched pre-treatment, mid-treatment and post-treatment samples from 20 TNBC 
patients (Table 5, Chapter 2). Matched blood samples were sequenced in parallel (mean depth 126×) 
Patient Time Point Depth Breadth Patient Time Point Depth Breadth
P1 PRE 135 0.997 P11 PRE 189 0.986
P1 OP 179 0.994 P11 MID 141 0.985
P1 BLOOD 96 0.997 P11 POST 144 0.985
P2 PRE 166 0.985 P11 BLOOD 172 0.986
P2 MID 153 0.986 P12 PRE 172 0.986
P2 POST 169 0.986 P12 MID 173 0.986
P2 BLOOD 161 0.986 P12 POST 153 0.986
P3 PRE 187 0.998 P12 BLOOD 111 0.985
P3 POST 171 0.998 P13 PRE 145 0.997
P3 BLOOD 135 0.998 P13 POST 143 0.997
P4 PRE 207 0.998 P13 BLOOD 89 0.997
P4 MID 117 0.998 P14 PRE 165 0.986
P4 POST 128 0.998 P14 MID 153 0.986
P4 BLOOD 83 0.998 P14 POST 172 0.986
P5 PRE 126 0.997 P14 BLOOD 119 0.985
P5 POST 104 0.997 P15 PRE 135 0.997
P5 BLOOD 128 0.998 P15 MID 105 0.996
P6 PRE 133 0.997 P15 BLOOD 109 0.996
P6 POST 209 0.998 P16 PRE 166 0.998
P6 BLOOD 124 0.997 P16 POST 149 0.997
P7 PRE 126 0.997 P16 BLOOD 186 0.998
P7 POST 104 0.997 P17 PRE 198 0.998
P7 BLOOD 128 0.998 P17 MID 234 0.998
P8 PRE 123 0.998 P17 BLOOD 172 0.998
P8 POST 127 0.998 P18 PRE 162 0.986
P8 BLOOD 100 0.997 P18 MID 164 0.986
P9 PRE 166 0.997 P18 POST 161 0.986
P9 MID 159 0.997 P18 BLOOD 139 0.986
P9 POST 127 0.997 P19 PRE 129 0.998
P9 BLOOD 107 0.997 P19 POST 192 0.998
P10 PRE 139 0.997 P19 BLOOD 95 0.997
P10 MID 111 0.996 P20 PRE 114 0.997
P10 POST 131 0.997 P20 POST 131 0.998
P10 BLOOD 102 0.997 P20 BLOOD 108 0.997
Table 5 - Sequencing depth and breadth for whole exome sequencing calculated for the patients 
at each time point.  Average sequencing depth was 173x for tumors and 126x for matched blood.  
Average breadth was >99% across all samples.  The columns in this table include: 1) patient 
identifier, 2) time point, 3) sequencing depth, 4) sequencing breadth 
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to distinguish somatic mutations.  Our data identified TP53 mutations in 60% (12/20) of the TNBC 
patients, consistent with frequencies reported in TCGA (13). On average, 49 nonsynonymous 
mutations (range 4-118) were detected in each patient.  Among the 20 patients, 10 showed no 
detectable mutations after treatment (Figure 16a), while 10 showed residual mutations after treatment 
(Figure 16b).  Notably, we did not observe an increase in mutation burden in response to NAC in 
any of the TNBC patients. 	
  We compared variant allele frequencies (VAFs) of somatic mutations before and after 
therapy (Figure 2C-D) and applied PyClone2 (100) followed by CITUP clustering analysis (143) to 
estimate clonal subpopulations from raw VAFs after normalization with copy numbers estimated by 
exomeCNV (210) and tumor purity estimated by ThetA (210) from exome copy number (Figure 16c-
d).  This analysis detected 2-4 major subclones in each TNBC patient and two distinct responses to 
NAC: 1) clonal extinction, wherein clones were completely eliminated (Figure 16c), or 2) clonal persistence, 
wherein clonal frequencies shifted but remained in the post-treatment samples (Figure 16d).  Indel 
frequencies corresponded with the categorization of clonal extinction and clonal persistence (Table 
6), as did ThetA-derived tumor purity, which also correlated with histopathological cellularity 
estimations (Table 7).  
Patient Chr Start End Ref Var Gene GenBank Exon Nucleotide Amino Acid Type PRE-TREATMENT VAF MID-TREATMENT VAF POST-TREATMENT VAF BLOOD VAF
P1 chr14 102906811 102906822 GCTTTTGCTTGT - TECPR2 NM_001172631 exon11 c.2617_2628del p.873_876del nonframeshift deletion 0.13 0.00 0.00
chr17 41246040 41246044 TTTAA - BRCA1 NM_007297 exon9 c.1363_1367del p.L455fs frameshift deletion 0.23 0.00 0.00
P6 chr5 57752903 57752903 - T PLK2 NM_006622 exon8 c.1024dupA p.R342fs frameshift insertion 0.40 0.00 0.00
chr11 65623457 65623476 GCATCATAGAGGGCATAGCG - CFL1 NM_005507 exon2 c.241_260del p.R81fs frameshift deletion 0.15 0.00 0.00
P7 chr17 76388613 76388613 C - PGS1 NM_024419 exon2 c.200delC p.S67fs frameshift deletion 0.67 0.09 0.00 0.00
P8 chr1 227174333 227174333 G - ADCK3 NM_020247 exon15 c.1839delG p.M613fs frameshift deletion 0.33 0.00 0.00
chr16 53496560 53496575 ATTTATCTGTGAGTAA - RBL2 NM_005611 exon11 c.1553_1560del p.D518fs frameshift deletion 0.23 0.00 0.00
chr16 56667697 56667707 GTGTGCCCACG AG MT1M NM_176870 exon3 c.129_139AG nonframeshift substitution 0.41 0.00 0.00
P9 chr16 72991713 72991715 CCA - ZFHX3 NM_006885 exon2 c.2330_2332del p.777_778del nonframeshift deletion 0.10 0.03 0.00 0.00
P10 chr2 43986106 43986106 C - PLEKHH2 NM_172069 exon27 c.4009delC p.R1337fs frameshift deletion 0.24 0.18 0.00 0.00
chr2 84928250 84928251 AA - DNAH6 NM_001370 exon49 c.7848_7849del p.S2616fs frameshift deletion 0.27 0.17 0.04 0.00
P11 chr1 27121265 27121265 - CA PIGV NM_001202554 exon3 c.740_741insCA p.T247fs frameshift insertion 0.23 0.09 0.01 0.00
P12 chr2 202359292 202359317 CAGGTTGTATTAGCAGGTCCTGCAGT - ALS2CR11 NM_001168221 exon15 c.1747_1772del p.T583fs frameshift deletion 0.33 0.00 0.02 0.00
chrX 92927966 92927986 TTTCTAAGCGCTTGCACACGA - NAP1L3 NM_004538 exon1 c.318_338del p.106_113del nonframeshift deletion 0.17 0.00 0.00 0.00
P14 chr1 7792556 7792556 G - CAMTA1 NM_015215 exon12 c.2963delG p.R988fs frameshift deletion 0.31 0.09 0.31 0.00
chr1 89848231 89848261 AATGAATAAGAAGGGGGATTTCTTGCTGCAG - GBP6 NM_198460 exon8 c.1161_1191del p.T387fs frameshift deletion 0.05 0.13 0.04 0.00
chr3 37107313 37107315 CTC - LRRFIP2 NM_017724 exon9 c.722_724del p.241_242del nonframeshift deletion 0.21 0.12 0.18 0.00
chr3 47048793 47048793 A - NBEAL2 NM_015175 exon47 c.7287delA p.I2429fs frameshift deletion 0.21 0.23 0.11 0.00
chr17 7577084 7577084 T - TP53 NM_001126115 exon4 c.458delA p.E153fs frameshift deletion 0.52 0.43 0.35 0.00
chr17 7756358 7756358 - GCC KDM6B NM_001080424 exon21 c.4651_4652insGCC p.R1551delinsRR nonframeshift insertion 0.27 0.16 0.15 0.00
P16 chr1 11889293 11889301 GTGGTGTTT - CLCN6 NM_001256959 exon12 c.1096_1104del p.366_368de nonframeshift deletion 0.21 0.00 0.00
chr3 128181899 128181899 G - DNAJB8 NM_153330 exon3 c.190delC p.L64fs frameshift deletion 0.19 0.00 0.00
P17 chr2 179441815 179441815 T - TTN NM_003319 exon152 c.42052delA p.S14018fs frameshift deletion 0.31 0.11 0.00
chr5 14610348 14610359 GGAGCCTCTCAG - FAM105A NM_019018 exon8 c.996_1007del p.332_336del nonframeshift deletion 0.01 0.17 0.00
chr5 132270172 132270214 GGAATGACTAGAGTTTAATGAAGAAACAGCCTGGGGTTTTCCA - AFF4 NM_014423 exon3 c.543_585del p.P181fs frameshift deletion 0.17 0.00 0.00
chr12 118671507 118671507 - CAAATAT TAOK3 NM_016281 exon9 c.614_615insATATTTG p.W205_S206delinsX stopgain 0.01 0.18 0.00
P19 chr1 197070598 197070599 TC - ASPM NM_018136 exon18 c.7782_7783del p.Q2594fs frameshift deletion 0.14 0.00 0.00
chr14 90429508 90429508 A - TDP1 NM_001008744 exon2 c.50delA p.E17fs frameshift deletion 0.00 0.15 0.00
chr17 7578222 7578223 TC - TP53 NM_001126115 exon2 c.230_231del p.R77fs frameshift deletion 0.11 0.00 0.00
chr17 10304270 10304271 TT - MYH8 NM_002472 exon26 c.3260_3261del p.E1087fs frameshift deletion 0.10 0.00 0.00
chr20 42682947 42682959 AGAAAAGAGACCT - TOX2 NM_001098796 exon5 c.534_546del p.G178fs frameshift deletion 0.10 0.00 0.00
Table 6 - Indels detected after local realignment with Mutect2, corresponding with somatic 
mutational classifications of clonal persistence and extinction.  The GBP6 indel in P6 has a raw post-
treatment VAF of 0.04 but only <6 indel reads, which would be filtered out according to somatic 
mutation filtration criteria.  The columns in this table include: 1) patient identifier, 2) chromosome 
number, 3) chromosome start position, 4) chromosome end position, 5) reference, 6) insertion or 
deletion, 7) gene, 8) exon, 9) nucleotide, 10) amino acid, 11) indel type, 12) pre-treatment VAF, 13) 
mid-treatment VAF, 14) post-treatment VAF, 15) blood germline VAF. 
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In the clonal persistence patients, most mutations were detected both pre-treatment and 
post-treatment but had decreased frequencies in response to NAC (Figure 16d).  However, we also 
identified a number of new mutations (N=34) that emerged in response to NAC (Table 8).  For 
Patient Time Point ThetA Purity Histopathological Cellularity Classification
P1 PRE 0.18 0 Extinction
POST 0.11 0
P2 PRE 0.18 0.2 Extinction
MID 0.18 0.15
POST 0.04 0.15
P3 PRE 0.33 0.5 Extinction
MID 0.25 0
POST 0.12 0
P4 PRE 0.46 NA Extinction
MID 0.15 NA
POST 0.09 NA
P5 PRE 0.52 0.38 Extinction
POST 0.15 0
P6 PRE 0.4 0.6 Extinction
POST 0.05 0
P7 PRE 0.46 0.65 Extinction
MID 0.13 0.15
POST 0.04 0
P8 PRE 0.32 0.9 Extinction
POST 0.03 0.2
P9 PRE 0.55 NA Extinction
MID 0.09 NA
POST 0.06 NA
P10 PRE 0.51 NA Persistence
MID 0.36 NA
POST 0.12 NA
P11 PRE 0.12 0.78 Persistence
MID 0.1 0.55
POST 0.05 0
P12 PRE 0.34 0.75 Persistence
MID 0.03 0.43
POST 0.12 0.1
P13 PRE 0.2 0.4 Extinction
POST 0.06 NA
P14 PRE 0.39 0.4 Persistence
MID 0.37 0.69
POST 0.37 0.75
P15 PRE 0.12 0.4 Persistence
MID 0.19 0.6
P16 PRE 0.19 0.6 Persistence
POST 0.06 0
P17 PRE 0.33 NA Persistence
MID 0.25 NA
P18 PRE 0.16 NA Persistence
MID 0.07 NA
POST 0.05 NA
P19 PRE 0.19 NA Persistence
POST 0.09 NA
P20 PRE 0.32 0.75 Persistence
POST 0.18 0.63
 NA = not available
Table 7 - Tumor purity determined by ThetA and by histopathological cellularity at different time 
points.  There was a high association between both ThetA and histopathological cellularity in 
classifying patients into the clonal persistence or resistance groups.  The columns in this table 
include: 1) patient identifier, 2) time point, 3) ThetA purity, 4) averaged histopathological cellularity, 
5) classification. 
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example, in P17, we detected 13 new nonsynonymous mutations that emerged after NAC at the mid- 
treatment time point, including nonsynonymous mutations in the apoptosis inhibitor, BIRC7, the 
actin binding protein, PARVG, and the solute carrier, SLC6A9, which had significant proposed  
 
 
 
 
≈ç	
Figure 16 - Bulk exome sequencing of matched longitudinal samples from 20 TNBC patients. (a) 
Number of nonsynonymous somatic mutations in patients with no residual mutations after NAC. (b) 
Number of nonsynonyous somatic mutations in patients with residual mutations after NAC.  (c) Line 
plots of raw variant allele mutation frequencies in left panels and inferred clonal subpopulations in 
clonal extinction patients in the right panels. (d) Line plots of raw mutation frequencies in left panels 
and inferred clonal subpopulations in right panels of clonal persistence patients.  Mutations that were 
specific to the post-treatment samples are highlighted in purple and labeled. (e) Targeted deep 
amplicon sequencing to validate of pre-existing resistance-associated mutations in four clonal 
persistence patients.  Stars indicate that the mutations were statistically significant (mutated, p<0.05) 
in the pre-treatment tumor samples by DeepSNV analysis. (f) A single patient (P19) in whom the 
resistance-associated mutations in the post-treatment tumor sample were not statistically significant 
(not mutated) in the pre-treatment tumor (ns, p>0.05) compared to the matched normal sample. 
a 
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functional impact based on SIFT (<0.05) (70) and POLYPHEN (P>0.85) scores (211).  Similarly, in 
patient P19, we identified 7 new mutations in the post-treatment sample, including a significant 
nonsynonymous mutation in the solute carrier SLC5A8.  While none of the resistance-associated 
mutations recurred across multiple patients, they did share common biological functions, including 
cell proliferation, apoptosis, solute transport, and cytoskeleton regulation (Table 8).   
We next asked whether the new mutations detected post-treatment were spontaneously 
induced due to acquired resistance, or alternatively, existed at very low frequencies pre-treatment, but 
were not detected due to the limited sensitivity of exome sequencing (mean 173×). To address this 
question, we selected a subset of post-treatment mutations (N=21) and performed targeted deep-
amplicon sequencing (789,000× mean depth) of the pre-treatment bulk tumor DNA (Table S9, 
Chapter 2).  We applied DeepSNV (144) to detect rare mutation frequencies that were statistically 
significant compared to matched blood (sensitivity of 1e4).  The amplicon data showed that in 4/5 
patients, the suspected de novo mutations did in fact occur at low frequencies in the pre-treatment 
e 
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tumor (range 0.1-2%), consistent with adaptive resistance (Figure 16e).  However, in one patient 
(P19), the de novo mutations were not statistically significant over the normal sample (Figure 16f).  
The mutations in this patients may have arisen de novo after the tumor cells were challenged with 
chemotherapy, or alternatively may have not been sampled due to insufficient sequencing depth, or 
sampling from different spatial regions.  
 
4.2.3 Copy Number Evolution and Clonal Extinction in Response to NAC 
To investigate copy number evolution in response to NAC, we performed single-nucleus sequencing 
(SNS) (12, 16) on 900 single cells from matched longitudinal samples of 8 TNBC patients (Methods 
Section 2.1.1).  We selected 4 clonal extinction patients (P1, P2, P6, P9) and 4 clonal persistence 
patients (P10, P11, P14, P15) from the exome data.  Single nuclei were isolated from aneuploid-gated 
Patient Gene Chr Pos Ref Var Mutation Type Validation PRE MID POST POLY SIFT Exon Nucleotide Amino Acid GenBank Gene Function
P10 PREPL chr2 44571019 T C nonsynonymous Yes 0.00 0.14 0.00 0.954 0.68 exon5 c.A481G p.I161V NM_001171603 serine-type endopeptidase activity
P10 KHDRBS2 chr6 62995789 A G nonsynonymous No 0.00 0.12 0.00 0.087 0.2 exon1 c.T65C p.V22A NM_152688 RNA-binding, alternative splicing 
P10 ZNF182 chrX 47837151 T C nonsynonymous Yes 0.00 0.21 0.00 0.02 0.31 exon6 c.A278G p.D93G NM_001007088 nucleic acid binding
P11 SHANK2 chr11 70331655 A G synonymous No 0.00 0.00 0.11 NA NA exon10 c.T2979C p.A993A NM_133266 postsynaptic activity
P14 SLCO1B3 chr12 21068984 G T nonsynonymous No 0.00 0.00 0.12 0.001 0.62 exon16 c.G1912T p.V638F NM_019844 ion channel activity
P14 DCHS2 chr4 155219314 G A nonsynonymous Yes 0.00 0.00 0.12 0.002 0.33 exon18 c.C4787T p.S1596L NM_017639 cell adhesion
P14 EIF2S2 chr20 32677631 C T nonsynonymous No 0.00 0.00 0.10 0.996 0.03 exon9 c.G907A p.E303K NM_003908 RNA-binding
P14 C10orf120 chr10 124457906 C T synonymous No 0.00 0.00 0.10 NA NA exon3 c.G351A p.P117P NM_001010912 ubiquitin ligase activity
P15 SPEF2 chr5 35763706 A T nonsynonymous Yes 0.07 0.13 - 0.006 0.88 exon26 c.A3703T p.M1235L NM_024867 protein dimerization
P15 ENAM chr4 71508463 C A synonymous No 0.00 0.092 - NA NA exon9 c.C1320A p.P440P NM_031889 mineralization of enamel
P15 OTOL1 chr3 161221587 G A nonsynonymous No 0.00 0.10 - 0 0.59 exon4 c.G1291A p.V431I NM_001080440 glycoprotein secretion
P15 C16orf71 chr16 4787886 A G nonsynonymous No 0.00 0.109 - 0.985 0.06 exon3 c.A215G p.D72G NM_139170 NA
P15 MYH9 chr22 36691666 G C nonsynonymous Yes 0.00 0.14 - 0.808 0 exon26 c.C3370G p.R1124G NM_002473 poly(A) RNA binding 
P17 KCNA10 chr1 111060626 G A nonsynonymous Yes 0.00 0.12 - 0 0.33 exon1 c.C784T p.L262F NM_005549 ion channel activity
P17 BRINP2 chr1 177226485 C G nonsynonymous Yes 0.00 0.16 - 0.999 0 exon4 c.C634G p.L212V NM_021165 cell cycle
P17 SRRM3 chr7 75894114 A G nonsynonymous Yes 0.00 0.11 - 0.993 0.46 exon9 c.A706G p.K236E NM_001291831 NA
P17 C8orf76 chr8 124250127 C T nonsynonymous No 0.00 0.13 - 0.983 0.21 exon3 c.G268A p.A90T NM_032847 G-protein coupled receptor activity
P17 OR5AS1 chr11 55798011 G T nonsynonymous Yes 0.00 0.12 - 0 0.02 exon1 c.G117T p.M39I NM_001001921 olfactory
P17 FLG chr1 152280610 C T nonsynonymous No 0.00 0.119 - 0.99 0.68 exon3 c.G6752A p.G2251E NM_002016 keratin intermediate filament aggregation
P17 CACNA1E chr1 181687234 G T nonsynonymous No 0.00 0.09 - 0.962 0 exon12 c.G1569T p.M523I NM_000721 voltage gated Ca2+ channel activity
P17 LARP1 0 154173703 G A synonymous No 0.00 0.18 - NA NA exon7 c.G882A:p V294V NM_015315 RNA cap binding
P17 UTP14A chrX 129053189 C T synonymous No 0.00 0.22 - NA NA exon6 c.C420T p.L140L NM_001166221 large ribonucleoprotein complex
P17 BIRC7 chr20 61870793 C T nonsynonymous Yes 0.00 0.25 - 0.998 0.1 exon6 c.C733T p.R245W NM_139317 enzyme binding
P17 PARVG chr22 44583712 C G nonsynonymous Yes 0.00 0.13 - 0.979 0.01 exon5 c.C201G p.S67R NM_001137605 actin binding
P17 SLC6A9 chrX 135106536 A C nonsynonymous Yes 0.00 0.132 - 0.956 0 exon12 c.A1414C p.T472P NM_006359 neurotransmitter:sodium symporter activity
P17 ELMO1 chr7 37253033 G T nonsynonymous Yes 0.00 0.228 - 0 1 exon12 c.C861A p.N287K NM_014800 binding
P18 RBM23 chr14 23371268 A G synonymous No 0.00 0.00 0.17 NA NA exon11 c.T1119C p.A373A NM_018107 RNA-binding
P19 SLC5A8 chr12 101555836 A G nonsynonymous Yes 0.00 - 0.11 1 0.01 exon13 c.T1546C p.W516R NM_145913 transporter activity 
P19 ACSL4 chrX 108906629 C G nonsynonymous Yes 0.00 - 0.10 1 0 exon14 c.G1516C p.G506R NM_022977 long-chain fatty acid-CoA ligase activity 
P19 RHAG chr6 49586961 A T nonsynonymous No 0.00 - 0.09 1 0 exon2 c.T272A p.L91H NM_000324 Rh transport
P19 ATG2B chr14 96773253 C T nonsynonymous No 0.00 - 0.10 0.977 0.31 exon30 c.G4304A:p G1435D NM_018036 autophagy
P19 TFPI chr2 188331710 G T nonsynonymous No 0.00 - 0.10 0.28 0.95 exon8 c.C868A p.Q290K NM_006287 blood coagulation, hemostasis
P19 BLNK chr10 97976416 A G synonymous No 0.00 - 0.10 NA NA exon7 c.T600C p.P200P NM_001258440 B cell development
P19 AP2A2 chr11 993298 C G synonymous No 0.00 - 0.13 NA NA exon12 c.C1470G p.P490P NM_001242837 binding / lipid binding
"-" = no sample
Table 8 - Table listing annotations in patients in whom new mutations were detected in the post-
treatment tissue samples that were not detected in the pre-treatment tumor samples or were detected 
at 2% ≤VAF.  Three mutations in the genes AMPH, SPEF2, and MYH9, were at 0-2% VAF at 
initial exome sequencing, but increased to 3-7% VAF after addition exome sequencing.  Columns in 
this table include: 1) patient identifier, 2) gene name, 3) chromosome number, 4) chromosome 
position, 5) reference base, 6) variant base, 7) synonymous or nonsynonymous mutation type, 6) 
status of whether the mutations was used for amplicon deep-sequencing, 7) pre-treatment mutation 
frequency, 8) mid-treatment mutation frequency, 9) post-treatment mutation frequency, 10) 
Polyphen prediction score for damaging impact, 11) SIFT prediction score for damaging impact, 12) 
exon number, 13) nucleotide site of mutation in the gene, 14) amino acid substitution within the 
protein, 14) genbank gene identifier, 15) extended gene function. 
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distributions with FACS and used for sparse (~0.1×) whole-genome sequencing.  The resulting data 
were used to quantify genomic copy number at ~220kb resolution (Methods Section 2.5).  FACS 
analysis of DAPI-stained  
 
 
Figure 17 – FACS profiles of a subset of patients before and after therapy.  (a) FACS profiles of 
DAPI-stained nuclei of 4 clonal persistence patients with identifiable aneuploid tumor peaks before 
and after treatment.  (b) FACS profiles of DAPI-stained nuclei from the 4 clonal extinction patients 
with aneuploid tumor peaks that were less prominent or absent after NAC treatment.   
a 
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nuclei showed that the 4 clonal persistence patients had aneuploid distributions in both the pre- 
treatment and post-treatment sample, while the 4 clonal extinction patients had low or undetectable 
aneuploid distributions post-treatment (Figure 17).  
To delineate the clonal substructure of the 4 clonal extinction patients, we obtained the 
common breakpoints across all the cells in the population (212) and performed optimal clustering 
(213) and t-SNE projection (214) using the short event matrix to avoid clustering artifacts that were  
 
Figure 18 – Copy number evolution in clonal extinction patients.  (a) t-SNE plots of single cell copy 
number profiles from the pre-treatment and mid-treatment or post-treatment samples of four clonal 
extinction patients with normal cells (N) and tumor subpopulations (A, B, or C) labeled. (b-e) 
Clustered heatmaps of single cell integer copy number profiles and consensus integer copy number 
profiles of clonal subpopulations.  Consensus line profiles show annotated cancer genes and 
subpopulation-specific differences indicated with grey bars.  Lower panels showed analyses of clonal 
dynamics calculated from optimal clustering results and maximal parsimony tree structures, and 
plotted in TimeScape with cancer gene and clonal frequencies annotated. 
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often introduced by parallel associations of uneven segment sizes (Methods Section 2.5). This 
analysis identified 2-3 clusters of aneuploid tumor cells and one cluster of normal diploid cells in each 
patient (Figure 18a).  The aneuploid clusters were found exclusively in the pre-treatment tissues, 
while the diploid clusters were mainly associated with the post-treatment tumor.  However, a few 
diploid stromal cells from the pre-treatment tumors also clustered with the post-treatment diploid 
cells.  Next, we computed consensus integer copy number profiles for each subclone, inferred clonal 
lineages (Figure 19a) using the maximal parsimony tree method (Methods Section 2.6) and plotted 
the clonal frequencies with Timescape (215).  These data identified two major clones in three patients 
(P2, P6, P9) and three major clones in the fourth patient (P1) in the pre-treatment tumors (Figure 18, 
Figure 19a).  Consensus profiles indicated that these multiclonal tumors shared common 
evolutionary ancestors, as evidenced by shared CNAs, including early events in MET, MYC, and 
PTEN in P6 (Figure 18b), MDM4, EGFR, and PTEN in P2 (Figure 18c), MYC and PTEN in P9  
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 (Figure 18d) and MYC, MET, TP53, CDKN2A and ALK in P1 (Figure 18e).  These tumors also had 
CNAs that emerged in the later stages of tumor evolution after diverging from a common ancestor.  
However, irrespective of the number of clonal subpopulations, NAC led to the extinction of tumor 
cells in these patients, with only diploid copy number profiles remaining after treatment. 
 
 
4.2.4 Adaptive Copy Number Evolution in Response to NAC 
Figure 19 - Maximum parsimony trees calculated from the consensus copy number event matrices 
for 4 extinction patients (A) and 4 persistent patients (B) with each subpopulation highlighted in a 
different color. The mutations labeled in the MP tree trunk were detected by piling up single cell 
copy number sequencing reads at known mutation sites detected by bulk exome sequencing. 
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To delineate copy number evolution in the 4 clonal persistence patients (P10, P11, P14, P15) we 
detected 2-5 clusters of aneuploid tumor cell copy number profiles (Figure 20a) and constructed 
maximum parsimony trees from the consensus clonal event matrix (Figure 19b).  Strikingly, we found 
that in all 4 patients, a minority of pre-treatment tumor cells (indicated with arrows) clustered with 
the post-treatment tumor cells, suggesting that they shared a resistant genotype.  To identify specific 
Figure 20 – Copy number evolution in clonal persistence patients.  (a) t-SNE plots of single cell 
copy number profiles from the pre-treatment and mid-treatment or post-treatment samples of four 
clonal persistence patients with tumor subpopulations (A,B,C,D,E) labeled.  Arrows indicate pre-
existing single cells from the pre-treatment samples that share the post-treatment chemoresistant 
copy number profiles. (b-e) Clustered heatmaps of single cell integer copy number profiles and 
consensus profiles of clonal subpopulations.  Consensus line profiles show annotated common 
cancer genes and subpopulation-specific differences indicated with grey bars.  Lower panels showed 
analyses of clonal dynamics calculated from optimal clustering results and maximal parsimony tree 
structures, and plotted in TimeScape with cancer gene and clonal frequencies annotated. Stars 
indicate the chemoresistant clones that were selected and expanded in response to NAC. 
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CNAs in the resistance-associated clones, we computed consensus copy number profiles from single 
cells (Figure 20b-e).  While most CNAs were shared between subclones, we identified specific CNAs  
that occurred exclusively in the chemoresistant clones.  In P14, resistance-associated clone A 
displayed two focal deletions on chr 3p, including a 5.26mb hemizygous deletion of 3p26 (IL5RA)  
and a 14.3mb hemizygous deletion of 3p24-22 (RARB).  This clone expanded after NAC from 7.7% 
to 71.8% post-treatment (Figure 20b).  In P10, two resistance-associated clones emerged after NAC, 
including clone C that expanded from 5.7% to 41.4%, and clone E that emerged mid-treatment at 
2.6% and expanded to 37.8% (Figure 20c). The resistance-associated clone C had a 22.85mb 
hemizygous deletion on chr 4p15 (PCDH7, DTHD1), a hemizygous deletion of a 5.75mb region on 
chr11q21-22 (MAML2) and chr13q (RB1, BRCA2, FOXO1).  In contrast, resistant clone E had a 
23mb amplification of chr 19p (JAK3, BRD4) and a 20mb deletion on chromosome 20 (PAK7). 
Expansion of the two minor clones with different genotypes suggests convergent evolution towards 
a resistant phenotype. CNAs specific to the resistant subclones were also identified in P11 and P15 
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by comparing consensus profiles (Figure 20d-e).  However, our data did not reveal any recurrent 
CNAs in the resistant clones among the 4 TNBC patients. Collectively, these results identified 
chemoresistance-associated CNAs that were pre-existing in the tumor mass and selected in response 
to NAC, supporting an adaptive resistance model in the clonal persistence patients.   
For an integration of single cell copy number with bulk mutation data, we used Samtools to 
pile up sparse single cell copy number reads to determine the presence of variant alleles at SNV sites 
that were detected by whole exome sequencing (Methods Section 2.3, Figure 19a-b). Due to the high 
sparseness of the single cell copy number data, we interpolated our observations to obtain maximal 
mutational information on known mutation sites. Any sites that had non-zero read counts of variant 
alleles in at least 2 cells were treated as mutated sites. We also interpolated the presence of a certain 
mutation in a single cell as the presence of the mutation in the whole subpopulation that the cell 
belonged to. With this approach, we were able to track truncal mutations that were shared by all 
subpopulations, but our data depth did not allow us to detect mutations that were unique to 
subpopulations. 
 
4.2.5 Transcriptional Programs of Tumor Cells in Clonal Extinction Patients 
We investigated phenotypic evolution in response to NAC using a high-throughput nanogrid single 
nucleus RNA sequencing (SNRS) method (207).  SNRS performs automated imaging and selection 
of up to 1,800 single nuclei in parallel for 3’ mRNA profiling. We profiled the transcriptomes of 
3,370 single nuclei isolated from two matched longitudinal samples per patient from the 4 clonal 
extinction patients (P1, P2, P6, P9).  An average of ~500 nuclei were selected from each time point 
for SNRS, which resulted in an average of 1.2 million reads and 4,107 genes detected per cell. To 
distinguish normal stromal cells from aneuploid tumor cells, we calculated copy number profiles 
from RNA read counts (47), using a set of 240 diploid normal breast cells from a different patient as 
a baseline reference (207) (Methods Section 2.8).  Clustered heatmaps identified a large number (90-
99%) of aneuploid tumor cells in the pre-treatment tumor but only diploid cells post-treatment,  
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Figure 21 – Transcriptomic evolution of clonal extinction patients.  (a) Heatmaps of single cell copy 
number profiles calculated from single cell SNRS data from pre-treatment and mid-treatment or 
post-treatment samples from 4 clonal extinction patients, clustered together with 240 normal breast 
cells from a different patient. (b) t-SNE projections of single cell RNA profiles from pre-treatment 
and mid-treatment or post-treatment samples from each clonal extinction patient.  (c) Violin plots of 
single cell RNA profiles for four cancer genes, TOP2A, RAN, DEK and CKS1B that were 
upregulated in the pre-treatment tumor cells across multiple patients. *, FDRadj p-value < 0.05, 
0.58=< |log2(foldchange)| <1;  **, FDRadj p-value < 0.05, |log2(foldchange)| >=1;  (d) Cancer 
gene signature analyses and clustering of GSVA scores for the tumor and normal cells from all 4 
clonal extinction patients. (e) t-SNE projection of all single cell data from the four clonal extinction 
patients, separating the tumor and normal cells in high-dimensional space. (f) Expression of 
fibroblast marker ACTA2 and epithelial marker EPCAM in the tumor and normal cells. (g) Normal 
cell type classification and frequencies in the post-treatment tissue samples. 
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consistent with the single cell copy number analyses (Figure 21a). We predicted the intrinsic breast 
cancer molecular subtypes (163) and found that all 4 TNBC patients were dominated by basal 
subtype of cells, but also had a small number of tumor cells with other subtype signatures (Figure 
22c). We identified differentially expressed genes between the pre-treatment tumor cells and post-
treatment normal cells (including fibroblast cells, basal and luminal epithelial cells) using the MAST 
e 
d 
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method, where we regressed out the batch effects caused by the single cell gene detection rates (160) 
(FDR-adjusted p-value < 0.05, |log2-fold change| > =1) (Methods Section 2.8) and performed high-
dimensional analyses to determine if tumor cells were present post-treatment (Figure 21b).  We also 
performed a parallel differential gene expression analysis without regressing out the gene detection 
rates in single cells, which revealed high concordance in detection of differentially expressed genes 
(72 – 99% concordance) in single cells (Figure 22a-b). This analysis identified distinct clusters of pre-
treatment and post-treatment cells, and further showed that no tumor cells were identified post-
treatment, suggesting that they were eliminated by NAC. However, a few diploid stromal cells (N=2-
9) from the pre-treatment tumors clustered with the post-treatment normal cells in patients P2, P6 
and P9.   
Differentially expressed genes in the 4 patients were identified and used to performed 2- 
dimensional clustering, which showed that a number of genes were upregulated in the tumor cells 
(mean = 590 genes) relative to the normal cells in the post-treatment samples, including several 
known cancer genes (NRAS, MYC, FGFR2, TP53) (Figure 23a).  In comparison to the post-
treatment normal cells, pre-treatment tumor cells displayed increased enrichment scores in the 
proliferation and regulation of apoptosis gene sets (Figure 23b-c).  While most cancer genes were 
unique to the individual patients, CKS1B, TOP2A, DEK and RAN were upregulated in multiple 
patients (Figure 21c, Figure 23a).  Notably, TO2PA has previously been shown to be a marker of 
sensitivity to anthracyclines in chemotherapy studies of breast cancer (216).  To determine if cancer 
phenotypes were shared across the TNBC patients, we performed GSVA analysis (164) and 
clustering on a set of cancer-specific signatures, which showed that the actin pathway, CDC42RAC 
pathway, proliferation (217), mTORC1 signaling, unfolded protein response, regulation of apoptosis, 
cancer meta signature (218), oxidative phosphorylation, and MYC targets (219) were upregulated in 
the sensitive tumor cells relative to the normal cells in the post-treatment samples (Figure 21d). 
We combined all the tumor and normal cell RNA data from the 4 patients, and performed a 
high-dimensional analysis of the gene signatures with t-SNE (Figure 21e).  The data showed that 
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 normal cells and tumor cells formed two distinct clusters.  Importantly, these data did not show any 
clustering of single cells by patient or batch, suggesting that batch effects were minimized in our 
datasets by using the normalized GSVA scores.  Within the normal cell cluster from the post-
treatment samples, we found high levels of the fibroblast marker, ACTA2, and within the tumor cell 
cluster from the pre-treatment samples, we found high levels of the epithelial marker, EPCAM 
Figure 22 - Venn diagrams of differential gene detection using MAST with or without single cell 
gene detection rate correction in 4 clonal extinction patients (a) and 4 clonal persistence patients (b).  
Classification of single tumor cells into the breast cancer subtypes (luminal A, luminal B, her2, basal 
or normal-like) based on PAM50 gene expression and ordered in pentagram graphs where each dot 
represents a single cell. (c) Breast cancer subtypes of clonal extinction patients in pre-treatment 
tumor cells. (d) Breast cancer subtypes of single tumor cells in clonal persistence patients before and 
after chemotherapy. 
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(Figure 21f). We further classified all normal cells in the post-treatment samples by 8 major breast 
cell types using cell-type specific markers, which showed that fibroblasts were the most abundant 
(mean 59.4% ± 16.2% SD) normal cells present after NAC, followed by T-cells (mean 6.9%) and 
other CD45+ immune cells (Figure 21g, Methods Section 2.8.8, Figure 23d).	
 
   
 
 
 
 
 
 
 
 
 
 
Figure 23 – Tumor and normal cell analyses of clonal extinction patients.  Clustered heatmaps of 
significant differentially expressed genes between pre-treatment tumor cells and post-treatment 
normal cells including fibroblasts and epithelial cells with cancer genes annotated (a). Boxplots of 
single cell geneset enrichment scores in extinction patients for the proliferation gene set (b) and the 
regulation of apoptosis gene set (c). Normal cell types were classified into 8 groups based on cell 
type-specific markers in the post-treatment normal cells from the 4 clonal extinction patients (d).  
Heatmaps indicate average expression of markers in single cells from each patient. 
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4.2.6 Acquired Evolution of Transcriptional Programs in Chemoresistant Tumor Cells 
To investigate phenotypic evolution in the clonal persistence patients (P10, P11, P14, P15), we 
conducted SNRS on ~400 nuclei from each matched time point, resulting in an average of 1.2 
million reads and 5,166 genes detected per cell.  The treatment time points for P11 and P15 were 
mid-treatment samples, while P10 and P14 included post-treatment samples.  We calculated copy  
b 
c 
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Figure 24 – Transcriptomic evolution of clonal persistence patients.  (a) Heatmaps of single cell 
copy number profiles calculated from single cell RNA data from pre-treatment and mid-treatment or 
post-treatment samples from 4 clonal persistence patients. (b) t-SNE projections of single cell RNA 
profiles from pre-treatment and mid-treatment or post-treatment samples from each clonal 
persistence patient, with arrow indicating two cells from the pre-treatment samples that cluster with 
the post-treatment expression profiles in patient P11.  (c) Venn diagrams and clustered heatmaps of 
significant differentially expressed genes between the pre-treatment tumor cells and post-treatment 
tumor cells with cancer gene annotations.  (d) Violin plots of single-cell GSVA scores for the pre-
treatment and post-treatment tumor cells from all 4 clonal persistence patients. (e) t-SNE projection 
of all single cell data from the four clonal persistence patients, separating the pre-treatment and post-
treatment cells in high-dimensional space irrespective of patient origin. First panel is colored by time-
point; fifth panel by patient, and other panels showed relative gene set enrichment scores for single 
cells. 
 a 
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number profiles from the single cell RNA read TPM data (Methods Section 2.8) and performed 1-
dimensional clustering (Figure 24a).  In contrast to the clonal extinction patients, a large fraction of 
aneuploid cells (85-99%) were detected in both the pre-treatment and post-treatment samples, 
consistent with the single cell copy number data. The few normal diploid cells that were detected in 
these samples were removed from subsequent expression analyses.   
To determine whether any of the tumor cells with chemoresistant expression profiles existed 
at low frequencies in the pre-treatment tumor, we performed high-dimensional analysis (Figure 24b, 
Chapter 2).  In three patients (P15, P14, P10), we did not detect any pre-existing transcriptional 
profiles that clustered with the post-treatment tumor cells, despite profiling hundreds of cells.  To 
identify genes upregulated in the chemoresistant post-treatment tumor cells, we performed 
differential expression analyses using MAST (FDR adj p-value < 0.05; |log2 fold change|>=1) and 
identified a number of differentially expressed genes (N=59-275) in each patient (Figure 24c).  A few 
differentially expressed genes were known cancer genes (MYC, ERBB3, KIT and PIK3R1) but were 
not recurrent among the patients (Figure 24c).  
e 
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 Molecular subtyping prediction showed that these tumors were prevalent with basal subtypes 
of cells except in one patient (P11) in which a number of tumor cells were classified as HER2+, as 
well as luminal A and B (Figure 22d).  Interestingly, P11 was HER2+ by IHC protein levels however 
did not have any copy number amplifications by FISH (Table 4).  These data show that the subtype 
composition of single cells did not change drastically in response to NAC, suggesting that subtype-
switching did not occur (Figure 22d). Next, we used t-SNE to cluster all the single cell data from the 
4 patients in high-dimensional space, which separated the pre-treatment and post-treatment tumor 
cells into two distinct clusters with single cells from different patients intermixed within each major 
cluster (Figure 24e). We labeled the chemoresistance gene signature scores of single cells in the high-
dimensional plots, which showed that they were highly enriched in the post-treatment samples, 
consistent with the gene signature heatmap clustering results (Figure 24e).  
To identify common phenotypes of the chemoresistant tumor cells, we performed single cell 
gene signature analysis using GSVA for a set of cancer-related signatures and clustered the 
normalized scores from all 4 patients (Methods Section 2.8.4, Figure 24d). This analysis showed that 
gene signatures including degradation of ECM, AKT1 signaling via mTOR (220), CDH targets (221), 
hypoxia (222), EMT and Angiogenesis were upregulated in the chemoresistant tumor cells after NAC 
(Figure 24e).  High expression of genes involved in AKT1 signaling via mTOR and hypoxia was 
associated with statistically significant worse survival (Figure 25), and hypoxia in particular was 
chemoresistance-associated because it did not affect survival in TNBC patients who did not receive 
chemotherapy (Methods Section 2.8.9).    
 To investigate whether resistance genes were partially activated in pre-treatment cells, we 
clustered pre-treatment single cells with post-treatment single cells in 4 persistent patients using a 
CNA matrix calculated from SAVER-rescued (223) single cell RNA sequencing data to define a 
group of non-resistant single cells that did not have resistant CNAs in pre-treatment tumors and a 
group of resistant single cells that had resistant CNAs in post-treatment tumors. We compared the 
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resistant single cells to non-resistant single cells using MAST and used the top variable genes (FDR 
adj p-value < 0.05; |log2 fold change|>=1.58) to perform random forest selection and to classify all 
single cells from each patient into the resistant or non-resistant group (Methods Section 2.9.2). In 
three patients (P10, P11 and P14), we detected pre-treatment cells (3-33 cells) that expressed a 
fraction of the resistant genes (Figure 26a-b), suggesting that although a pre-existing genotype may 
prime cells, a second step of phenotype switching is required for resistance activation.  In order to 
integrate mutational subpopulations with single cell RNA data, we tracked mutations that were 
present in the 3’-ends of transcripts.  However, due to the sparseness of the single cell RNA 
sequencing reads, we were only able to use this approach to confirm our classifications of persistence 
and extinction patients (Figure 26c-d).   
 
4.3 Discuss ion  
In this study we investigated genomic and phenotypic evolution of TNBC patients in response to 
Figure 25 - Survival analysis from the METABRIC dataset for breast cancer patients that received 
chemotherapy, grouped by the enrichment scores of six selected gene sets that were enriched in post-
treatment resistant cells. 
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treatment, including many fibroblasts and immunocytes. In contrast, in the clonal persistence 
clonal extinction patients, NAC eliminated the tumor cells, leaving only normal diploid cells after  NAC, wh ch revealed two distinct classes of clonal dynamics: extinction and pers stence.  In the  
Figure 26 – Integration of genomic and phenotypic data.  a) Prediction of resistance activation in 
single cells in 4 persistence patients. Labels are colored by NAC time point. Single cells defined as 
primed pre-treatment cells that had resistance activation scores above 17.2% are illustrated as blue 
stars. (b) t-SNE projection of pre-treatment single cells (blue) and post-treatment single cells (red). 
Primed pre-treatment single cells are highlighted with turquoise stars. Oncomap of somatic 
mutations from whole exome sequencing that were also detected in single cells via reads from single 
cell RNA sequencing.  Detected variants noted in red, detected reference bases noted in white, and 
low-coverage reads (<2 reads at the site) noted with a diagonal line.  Patient classifications of clonal 
persistence and extinction were maintained in the single cell RNA sequencing data, with clonal 
persistence patients (c) demonstrating residual mutations by RNA sequencing and clonal extinction 
patients (d) demonstrating elimination of mutations.  (e) Adaptive evolution in response to 
neoadjuvant chemotherapy (NAC) leads to the selection of minor clones with chemoresistant 
genotypes and phenotypes. (f) Acquired evolution in response to NAC leads to induction of new 
mutations and phenotypes in response to the therapeutic agent. (g) Adaptive genomic and acquired 
phenotypic evolution occurs in two steps, wherein the genotypes are first selected and expanded in 
response to NAC after which transcriptional reprogramming occurs leading to chemoresistant 
phenotypes in primed cells. 
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patients, the post-treatment tumors harbored a large number of tumor cells with genotypes and 
phenotypes that were altered in response to NAC. Using single cell DNA and RNA sequencing 
methods we performed a higher resolution analysis of 8 patients, which showed that CNAs that 
emerged in response to NAC were pre-existing and adaptively selected, while the expression profiles 
were mostly acquired through transcriptional reprogramming.  We speculate that the genotypes 
selected by NAC are primed for transcriptional reprogramming and therefore provide an 
evolutionary advantage over tumor cells that are sensitive to chemotherapy (Figure 26e).  
Collectively, our data suggest that chemoresistance evolution is mediated by the adaptive selection of 
genomic aberrations and transcriptional reprogramming to establish the resistant tumor mass. 
 Our study is particularly novel because it uses both single cell DNA and single cell RNA 
sequencing to delineate the evolution of TNBC tumors in response to chemotherapy.  Although our 
previous work has investigated genomic evolution in TNBC at single-cell resolution (16, 17), and 
other studies have applied single cell RNA sequencing to TNBC (19), the present study is significant 
because it demonstrates how genomic and phenotypic evolution display two different methods of 
chemoresistance across longitudinal samples.  Without conducting both DNA and RNA single cell 
sequencing, we would not have been able to identify the process of chemoresistance evolution in 
TNBC wherein mutations and CNAs are adaptively selected and prime cells for acquired 
transcriptional reprogramming.  
          Our data in TNBC patients contrast with previous genomic studies in other human cancers, in 
which chemotherapy in glioblastoma and ovarian cancer show large increases in mutation frequencies 
in the post-treatment sample (24, 63, 127).  In our exome data, we observed decreases or no changes 
in the mutation frequencies in the post-treatment samples in response to NAC. These data may 
reflect the different chemotherapeutic agents that were used to treat the glioblastoma and ovarian 
cancer patients, since cis-platinum and telozolomide have been shown to be highly mutagenic.  In 
contrast, neoadjuvant chemotherapy in this study included taxanes (paclitaxel), anthracyclines 
(epirubicin) and angiogenesis inhibitors, which are not known to be highly mutagenic.  Our results 
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are consistent with a previous study in TNBC, which reported no significant increase in somatic 
mutations after treatment with chemotherapy (15).   
 While the mutations and CNAs that were selected in response to NAC constituted diverse 
biological functions, the transcriptional programs indicated several common gene signatures and 
pathways associated with chemoresistance across the 4 patients.  Some gene networks relate directly 
to the responses from the therapeutic agents, while others are likely to be associated with resistance 
mechanisms.  For example, the mesenchymal phenotypes we observed in post-treatment tumor cells 
have been shown to desensitize tumors to cytotoxic agents (88).  Studies using immunocytochemistry 
have also showed that breast tumor cells in post-NAC samples harbor mesenchymal phenotypes 
associated with resistance (65), consistent with our data.  In the context of therapy, decreased anoikis 
permits cancer cells to survive upon detachment from the ECM to gain metastatic potential (224), 
while TNF signaling can alter the tumor microenvironment, inducing angiogenesis, EMT, and ECM 
remodeling (225).  These phenotypes may play an important role in conferring a chemoresistant 
phenotype, but will require future functional studies using in vitro and in vivo models to understand 
their mechanisms. 
          Our data has several important clinical implications. First, the pre-existence of chemoresistant 
genotypes in the tumor mass indicates there may be diagnostic opportunities for detecting 
chemoresistant clones in TNBC patients before NAC, to predict which patients are most likely to 
benefit from chemotherapy. Second, the stratification of TNBC patients into clonal extinction and 
clonal persistence groups may have prognostic implications for predicting patient outcome or 
survival, however such studies will require larger cohorts of patients with longitudinal samples.  
Third, our data on chemoresistant phenotypes raise the possibility of therapeutic strategies to 
overcome chemoresistance, such as targeting EMT signaling (226) or TNF signaling (227) to 
resensitize the tumor cells to chemotherapy and eliminate the tumor mass.   
          Notable limitations to our study include the total number of patients (N=8) that were analyzed 
at single cell resolution.  Future work will need in a larger cohort of TNBC patients to understand the 
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generalizability of the chemoresistance-associated phenotypes and the evolutionary model that was 
identified in this study.  Although batch effects have been identified as a major confounding effect in 
single cell RNA data (228), we mitigated these errors by processing all samples in parallel, using 
identical reagents, and correcting for batch effects in our data post-processing steps.  The global 
analysis of the tumor cells in high-dimensional space, shows that single cells cluster by treatment time 
point rather than by patient, suggesting that batch effects did not significantly affect our datasets 
when using individually normalized single cell GSVA scores.  Another potential source of error is in 
spatial bias in the core biopsy samples, which we mitigated by using two independent ultrasound-
guided core biopsy samples from each time point and by using large surgical specimens from the 
post-treatment time points.   
          In closing, we expect that the approach reported here will provide new insights into 
chemoresistance evolution in many human cancer types.  In most human cancers chemotherapy 
remains to be the first line of therapy and standard of care, in which the tumors often respond well 
initially but frequently develop resistance within the first few years.  Important future directions will 
also include the analysis of metastatic tumors that are matched to primary tumor samples from the 
same TNBC patients, to understand whether the chemoresistant clones in the primary seed 
metastases and also confer resistance at distant organ sites. These studies will become more feasible 
as single cell DNA sequencing technologies increase in throughput and decrease in cost (181), and 
the ability to sequence both DNA and RNA in the same cell becomes more technically accessible 
and high-throughput (126).  
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
 
5.1 Conc lus ions  
In my dissertation, I demonstrate the phenotypic heterogeneity of TNBC tumors by developing a 
nanogrid-based single-nucleus sequencing method that can be applied to frozen tissue samples.  I 
also delineate the genomic and phenotypic evolution of 8 TNBC tumors in response to 
chemotherapy with deep WES, single-cell copy number sequencing, and single-nucleus RNA 
sequencing.  In patients with clonal persistence of somatic mutations, genomic resistance is adaptive 
through the expansion of pre-existing mutations and copy number aberrations.  Conversely, 
phenotypic resistance driven by reprogrammed transcriptomic programs that confer a chemoresistant 
phenotype.   
 This study is particularly novel because it uses both single cell DNA and single cell RNA 
sequencing to delineate the evolution of TNBC tumors in response to chemotherapy.  Although 
previous work has investigated genomic evolution in TNBC at single-cell resolution (16, 17), and 
other studies have applied single cell RNA sequencing to TNBC (19, 229), the present study is 
significant because it shows how genomic and phenotypic evolution display two different methods of 
chemoresistance across longitudinal samples.  Without conducting both DNA and RNA single cell 
sequencing, I would not have been able to identify the process of chemoresistance evolution in 
TNBC wherein mutations and CNAs are adaptively selected and prime cells for acquired 
transcriptional reprogramming.  These final conclusions of my dissertation are based on a NGS 
approach with the primary objective of investigating chemoresistance in TNBC from an unbiased 
genome-wide perspective.  They inform us of the common evolutionary paths that exist in the 
context of chemoresistance for TNBC patients and emphasize the importance of conducting both 
DNA and RNA analyses in the same longitudinal samples.    
 
 
5.2 Future  Dire c t ions  
5.2.1 Advances in Single-Cell Epigenetics and Whole Genome Sequencing 
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Within the genomics-based scope of my thesis project, I can only theorize the mechanisms of 
adaptive genomic resistance and acquired phenotypic resistance in TNBC.  The first theory is 
epigenetic modification of genotypes that are primed to produce chemoresistant phenotypes.  Since 
resistance-associated somatic mutations and CNAs pre-exist prior to treatment, perhaps they are 
uniquely equipped to undergo reversible epigenetic changes that influence gene expression and 
consequently alter cell phenotypes.  Recent studies in high-throughput epigenetic SCS(49, 113) have 
successfully identified differential methylation patterns that affect transcription, and there are many 
single-cell epigenomic methods that can resolve the epigenetic states of individual cells(230).  These 
approaches can determine the regions of the genome that experience epigenetic changes during 
chemoresistance evolution.   
In light of the fact that the exome comprises only a small fraction of the entire genome, I 
also posit that mutations in the noncoding genome affect the phenotypic plasticity of chemoresistant 
cells.  Conceivably there are differences between the whole-genome mutational profiles of 
chemoresistant cells versus non-chemoresistant cells, with chemoresistant cells potentially harboring 
key adaptive resistance-associated mutations in noncoding genes that are absent in chemosensitive 
cells.  Although it is difficult to gauge the functional significance of noncoding mutations, they may 
be just as important as coding mutations in their ability to experience epigenetic modifications and 
alter phenotypes.  Currently, the field of cancer genomics is limited by the high-cost and low-
throughput nature of single-cell WGS, but future technological advances can increase the feasibility 
of examining the noncoding genome in chemoresistance evolution.    
 
5.2.2 Associations Between Genotype and Phenotype 
Although separate genomic and phenotypic analyses provide key details to chemoresistance, an 
integration of genomic and phenotypic data is the most direct way of assessing both aspects of tumor 
evolution.  Future work should investigate modes of chemoresistance evolution in the same cells at 
single-cell resolution.  In Chapter 1, I reference advances in next-generation sequencing that allow 
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genome and transcriptome sequencing from the same cell and note the low-throughput nature of 
these new methods.  Potential alternatives include calling mutations in full-length RNA 
transcripts(43), sequencing DNA and RNA from the same cell(73), or extracting more specific CNA 
data from RNA sequencing(231) in order to determine that cells with chemoresistant gene signatures 
also harbor pre-existing resistance-associated somatic mutations or CNA profiles. 
Phenotypes themselves quite possibly exist on a gradient that begins with the early stages of 
carcinogenesis and eventually leads to chemoresistance.  In Chapter 4, I identify several gene 
signatures and transcriptional programs that are acquired after chemotherapy, but it is difficult to 
ascertain whether individual signatures portend chemoresistance or whether an aggregation of 
different signatures is required to achieve that phenotype.  This is further complicated by the 
possibility that a different single-cell RNA sequencing method would have been able to detect more 
genes and therefore provide more comprehensive resistance-associated phenotypes.  Furthermore, 
without functional studies, I can only postulate from my NGS observations that the identified 
signatures contributed extensively to chemoresistance.  As a result, the phenotypic evolution data will 
ostensibly benefit the most from functional validations as well as cross-validations with alternative 
RNAseq methods.  Individual genes, combinations of genes, or entire gene signatures identified in 
silico can be experimentally overexpressed or knocked out to evaluate effects on chemoresistance in  
vitro. 
 
5.2.3 Single Cell Sequencing in the Tumor Microenvironment 
Single cell sequencing enables an in-depth analysis of not only tumor cells but also cells present in the 
surrounding microenvironment.  In doing so, it allows us to study the non-tumor factors, such as 
immunocytes and normal cells, which shape tumor evolution.  By investigating the tumor 
microenvironment, we can determine the underlying causes of intratumor heterogeneity in the 
context of environmental alterations and explain why tumor clones and subclones persist despite the 
body’s immune defenses.  For example, paired single cell sequencing of stage I lung adenocarcinoma 
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tumor cells, normal cells, and immunocytes reveals a relative increase in T cells and mononuclear 
phagocytes in tumor tissue versus normal tissue(232).  Likewise, in primary breast cancer of various 
subtypes, single cell RNAseq indicates a preponderance of immunosuppressive T lymphocytes 
(regulatory or exhausted phenotype) or M2 macrophages(19).  Identification of aberrant 
immunocytes in tumors can potentially elucidate methods to overcome resistance to immunotherapy 
across different cancer types(233) 
 
5.2.4 Clinical Potential and Precision Medicine 
An ongoing theme throughout this thesis is the superior capacity of single cell sequencing to find and 
to characterize cells that influence medically relevant phenotypes.  With its high resolution, single cell 
sequencing has the potential to identify rare populations that harbor robust clinical consequences, 
such as drug resistance and metastasis.  Conveniently, advances in single cell sequencing have 
coincided with advances in targeted genome editing, and an integration of these modalities can 
inform and amend precision medicine.  
 We start with a scenario where we characterize metastatic subclones by conducting single-
cell comparisons between a primary tumor and its corresponding metastatic site.  We then verify the 
functional significance of the genes in the metastatic subclone through a CRISPR-Cas9 screen that 
determines whether a particular gene of interest wields a driving influence on metastasis.  Finally, we 
pool together targeted knockouts of the screened genes for an in vitro or in vivo (xenograft) 
experiment to observe whether knocking out drivers will affect metastatic rate.  This last step can be 
altered to include therapies that target validated sets of genes.  
 Here it is important to note that segments of our overall approach have been previously 
published or at least have proven to be feasible.  Single cell transcriptome analyses of head and neck 
squamous cell carcinomas and their matched lymph node metastases have identified a partial EMT 
signature that exists in the primary tumors as a precursor to the full EMT signature present in the 
lymph nodes(234).  Our own data in the context of chemoresistance display a similar pattern, where 
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single cell sequencing reveals primed signatures in the pre-treatment biopsies (Chapter 4).  Both 
positive and negative CRISPR-Cas9 screens have also been used to distinguish genes that are 
necessary for cancer cell survival or confer resistance to cancer therapies(235).  Although there are no 
existing studies that combine single cell sequencing with targeted genome editing, this integration is 
certainly a realistic endeavor.  From a clinical perspective, it allows us to: 1) pinpoint genes with 
potential phenotypic importance at single-cell resolution, 2) test the functional significance of the 
genes with high-precision genome editing, 3) evaluate the aggregate phenotypic benefits of pooled 
genome editing, and 4) find therapies, therapeutic combinations, and therapeutic sequences for gene 
sets with confirmed phenotypic significance (under the presumption that genome editing has not yet 
been approved for clinical use).   
The aforementioned process is not necessarily limited to cancer, and there are many 
branches of medicine that could benefit from high-resolution sequencing and high-precision genome 
editing.  One option is the application to progressive chronic kidney disease (CKD), where the 
transition to end-stage renal disease (ESRD) is multifaceted and involves stepwise deficits in different 
renal structures.  Multi-region single cell sequencing of the kidney at different CKD time points in 
experimental models of renal failure can elucidate the genotypic, phenotypic, and anatomical 
progression to ESRD.  Furthermore, a detailed analysis at various stages of kidney injury can shed 
light on potential protective mechanisms against further deterioration. 
  
5.2.5 Importance of Single-Cell Sequencing 
The results of this dissertation attest to the two-fold importance of single-cell sequencing in defining 
rare cellular populations: 1) single-cell sequencing at the RNA level can preferentially isolate and 
profile tumor cells after distinguishing them from normal cells with copy number profiles inferred 
from RNAseq and 2) single-cell CNA and RNA sequencing can identify profiles that exist in minor 
fractions of cells.  We strongly believe that the pre-existing genotypic populations would not have 
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been identified with bulk sequencing.  Similarly, we posit that that bulk RNA sequencing would have 
been confounded by stromal contamination and immunocyte infiltration. 
 
5.3 Limita t ions  and Looking  to  the  Long-Term Future   
(aka Pipe Dreams) 
As geneticists in the era of tremendous technological advances, we often feel a premature urgency to 
emphasize the practical and clinical benefits of next-generation sequencing and big data genomics.  
Every presentation on cancer genomics touts the applicability of genomic sequencing methods to 
human patients – from early tumor detection to precision medicine.  However, bench-to-bedside 
translations are not infrequently obstructed by various logistic problems inherent to the approach 
and design of genomic studies.  Firstly - to the exclusion of a pan-cancer paradigm – much of clinical 
oncology is still stratified into organ systems and disease sites.  Although TCGA has pursued a pan-
cancer research initiative that analyzes common aberrations across different tumor types, this line of 
thinking has not yet been integrated into the clinic.  Perhaps we will benefit from a future generation 
of oncologists who can evaluate the significance of genomic and phenotypic aberrations across 
tumor types as well as within specific organs.   
 Secondly, NGS studies can be under-powered, restricted by the availability of patient 
samples, resulting in scientific conclusions that are applicable to only a controlled subset of patients.  
Indeed, larger sample sizes are needed to validate results and generalize them for functional 
purposes.  When prospective studies are not feasible, existing data sets, such as the ones from 
TCGA, can now be explored with specialized pipelines and new hypotheses.  Ongoing projects 
headed by Leroy Hood’s Institute for Systems Biology (ISB), in collaboration with the NCI, facilitate 
access to TCGA data through implementation of an interactive cloud system (ISB Cancer Genomics 
Cloud).  These cloud-based improvements mitigate the unwieldiness of big data and streamline the 
TCGA database for customizable analyses.  We can potentially gain more robust insights into cancer 
via enhanced access to existing data sets. 
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 Thirdly, there is a possibility that the volume of information we can now acquire from 
patients has exceeded the limits of human computation and assessment.  “Cognitive computing”, 
aided by machine-learning algorithms (e.g. IBM Watson), incorporates large quantities of clinical data 
into the contexts of therapies, available trials, and treatment sequences – far beyond the capacity of 
human processing.  It is not unreasonable to imagine that in the not-so-distant future, machine 
learning will use many different forms of NGS data to direct clinical decisions.  
Fourthly, genomic information attained from FNAs or core biopsies may reflect geographic 
biases, as some regions of the tumor are difficult to radiographically visualize and sample.  This is a 
topic that is of special interest, because it involves a branch of medicine that has recently emerged as 
its own specialty.  Interventional radiology (IR), previously a fellowship after a diagnostic radiology 
residency, is now an independent training program for minimally invasive techniques/treatments and 
image-guided procedures.  IR physicians use various imaging modalities, including CT, MRI, and 
ultrasound, for their biopsies – and correlative studies in IR can reveal associations between certain 
cancer types and the efficacy of different imaging approaches.  For instance, malignant tissues may 
differentially take up fluorodeoxyglucose, causing tumors of a certain subtype to be more accurately 
visualized with PET/CT for biopsy guidance.  Research in IR can distinguish tumor characteristics to 
select the imaging modalities that produce the most representative biopsy sections.  
 
 
With these future directions in mind, I end on a hopeful note that our ever-broadening innovations in genomic technology 
and medicine will help us address existing challenges in cancer treatment. 
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